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Abstract
Epigenetic mechanisms regulate chromatin structure and gene expression to direct organismal
development and tissue homeostasis, disruption of which is pervasive in cancer. Epigenetic disruption
can lead to the acquisition of each hallmark of cancer and almost half of all human cancers bear
mutations in epigenetic regulators. The histone methyltransferase MLL4 (KMT2D) has been described as
an essential gene in both humans and mice. In addition, it is one of the most commonly mutated genes in
all of cancer biology with the highest frequency of mutation occurring in cutaneous squamous cell
carcinomas (cSCC). The opposing demethylase LSD1 acts in a genetic and epigenetic axis with MLL4 and
is highly overexpressed in various human cancers, which has resulted in the development of highly
specific and potent LSD1 inhibitors. Despite this, how the MLL4-LSD1 epigenetic axis regulates normal
epidermal homeostasis or becomes dysregulated to drive cSCC tumorigenesis is not well understood.
Here, using transgenic mouse models, next-generation sequencing, and human skin models, we address
this gap in knowledge. First, we identify a critical role for Mll4 in the promotion of epidermal
differentiation and ferroptosis, a key mechanism of tumor suppression. Mice lacking Mll4, but not Mll3
(Kmt2c), display features of impaired differentiation and human precancerous neoplasms, all of which
progress with age. Mll4 deficiency profoundly alters epidermal gene expression and uniquely rewires the
expression of key genes and markers of ferroptosis (Alox12, Gpx4, Slc7a11). Beyond revealing a new
mechanistic basis for Mll4-mediated tumor suppression, our data uncover a potentially much broader and
general role for ferroptosis in the process of differentiation and skin homeostasis. In addition to these
findings, we also show that LSD1 directly represses master epithelial transcription factors that promote
differentiation. LSD1 inhibitors block both LSD1 binding to chromatin and its catalytic activity, driving
significant increases in H3K4 methylation and gene transcription of these fate-determining transcription
factors. This leads to both premature epidermal differentiation and the repression of features squamous
cell carcinoma. Together, this work reveals critical functions for the MLL4-LSD1 epigenetic axis during
epidermal differentiation, ferroptosis, and tumorigenesis and offer new therapeutic strategies to be tested
for the treatment of cSCC.
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Abstract
THE MLL4-LSD1 EPIGENETIC AXIS REGULATES EPIDERMAL DIFFERENTIATION
AND FERROPTOSIS: IMPLICATIONS FOR SKIN CANCER

Shaun Egolf
Dr. Brian Capell
Epigenetic mechanisms regulate chromatin structure and gene expression to
direct organismal development and tissue homeostasis, disruption of which is pervasive
in cancer. Epigenetic disruption can lead to the acquisition of each hallmark of cancer
and almost half of all human cancers bear mutations in epigenetic regulators. The
histone methyltransferase MLL4 (KMT2D) has been described as an essential gene in
both humans and mice. In addition, it is one of the most commonly mutated genes in all
of cancer biology with the highest frequency of mutation occurring in cutaneous
squamous cell carcinomas (cSCC). The opposing demethylase LSD1 acts in a genetic
and epigenetic axis with MLL4 and is highly overexpressed in various human cancers,
which has resulted in the development of highly specific and potent LSD1 inhibitors.
Despite this, how the MLL4-LSD1 epigenetic axis regulates normal epidermal
homeostasis or becomes dysregulated to drive cSCC tumorigenesis is not well
understood. Here, using transgenic mouse models, next-generation sequencing, and
human skin models, we address this gap in knowledge. First, we identify a critical role
for Mll4 in the promotion of epidermal differentiation and ferroptosis, a key mechanism of
tumor suppression. Mice lacking Mll4, but not Mll3 (Kmt2c), display features of impaired
differentiation and human precancerous neoplasms, all of which progress with age. Mll4
deficiency profoundly alters epidermal gene expression and uniquely rewires the
expression of key genes and markers of ferroptosis (Alox12, Gpx4, Slc7a11). Beyond
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revealing a new mechanistic basis for Mll4-mediated tumor suppression, our data
uncover a potentially much broader and general role for ferroptosis in the process of
differentiation and skin homeostasis. In addition to these findings, we also show that
LSD1 directly represses master epithelial transcription factors that promote
differentiation. LSD1 inhibitors block both LSD1 binding to chromatin and its catalytic
activity, driving significant increases in H3K4 methylation and gene transcription of these
fate-determining transcription factors. This leads to both premature epidermal
differentiation and the repression of features squamous cell carcinoma. Together, this
work reveals critical functions for the MLL4-LSD1 epigenetic axis during epidermal
differentiation, ferroptosis, and tumorigenesis and offer new therapeutic strategies to be
tested for the treatment of cSCC.
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Chapter 1: Introduction
This chapter includes work adapted from previously published manuscripts in Trends in
Genetics [1] and Expert Opinion on Therapeutic Targets. [2]

1.1 Histone modifiers regulate cellular fate, identity, and disease
1.1.1 Epigenetic mechanisms regulate chromatin and gene expression
Multicellular organisms, such as humans, develop with genetically identical
somatic cells, each containing the same DNA sequence. Despite this, the human body
has hundreds of cell types with remarkable differences in form and function. These
unique cellular phenotypes are achieved via cell-intrinsic and -extrinsic regulatory
mechanisms that govern the differential activation or silencing of genes. A key mode of
regulating these distinct gene expression patterns is through epigenetic mechanisms,
which occur independently of any changes to the DNA sequence [3]. Under this
definition, epigenetics encompasses a wide range of regulatory processes. Used here,
the word epigenetic more specifically refers to those mechanisms that regulate gene
expression by altering DNA organization and accessibility.
The most basic level of genomic organization is the nucleosome, comprised of
147 base pairs of DNA wrapped around eight histone proteins. Each octamer of histones
contains two of each of the principal histones, H2A, H2B, H3, and H4, or their variants.
This organization significantly compacts the genome, and the resulting macromolecular
complex of DNA and proteins is referred to as chromatin. Nucleosomes are then further
organized into fibers and loops that allow for additional compaction and ultimately are
packaged into complex, higher-ordered structures. By modulating this intricate
organization, epigenetic regulation can dynamically control gene expression by making
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particular genomic regions more or less accessible [4]. Making chromatin more open
tends to increase transcription, while chromatin compaction will silence transcription [5].
A primary mode of epigenetic regulation is the post-translational modification of
histone tails. At least 60 different covalent chemical modifications of histones have been
described, including various forms of acetylation, methylation, phosphorylation, and
ubiquitylation [6]. These histone marks impact chromatin structure by both altering the
physical noncovalent interactions of nucleosomes, as well as by recruiting chromatin
remodeling complexes [7]. Consequently, particular histone modifications are correlated
with specific chromatin states. For example, some of the most well-studied methylated
lysines on histone H3 are associated with transcriptional activation (e.g., H3K4me3,
H3K36me3, H3K79me3), transcriptional repression (e.g., H3K27me3), or DNA repeat
and centromeric silencing (e.g., H3K9me3) [5]. Collectively, this establishes an
impressively complex system for the fine-tuning of gene regulation commonly referred to
as the “histone code” [8]. For instance, embryonic stem cells exist in a bivalent state,
where they are marked by both the activating histone modification, H3K4me3, as well as
the repressive modification, H3K27me3 [9]. From this state the genes are considered to
be ‘poised’ and primed either for activation or for repression, depending upon their
ultimate cell fate. The histone code is written (added), erased (removed), and read
(identified) with extreme specificity by a host of well-characterized histone modifier
enzymes. Understanding how these histone modifiers function in normal physiology,
become dysregulated in disease, and may be targeted therapeutically has emerged as
an exciting area of research with untapped clinical potential.
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1.1.2 Epigenetics in physiology and human disease
Given their essential roles in regulating chromatin accessibility and gene
expression, epigenetic processes are critical for various normal physiological processes.
These include establishing and maintaining cellular fate and identity, differentiation,
homeostasis, and organismal development [10, 11]. Acting in concert with transcription
factors, chromatin modifiers establish the epigenetic landscape, both enabling and
stabilizing cell type-specific gene expression, while simultaneously repressing alternative
cell fates [9]. This simultaneously forms an epigenetic barrier that prevents cells from
returning to the stem cell state. Consequently, chromatin profiles alone in differentiated
cells are often sufficient for identifying cell type, particularly at key regulatory gene
enhancer nodes [10, 11]. Beyond the period of embryonic development, epigenetic
mechanisms continue to coordinate the balance between adult stem cell renewal and
differentiation [12]. This epigenetic balance is essential, as impaired self-renewal can
lead to stem cell exhaustion and aging, while excessive self-renewal may promote
cancer [4].
Consistent with this idea, epigenetic regulators are mutated across almost half of
all human cancers [13] and epigenetic biomarkers have proven useful in monitoring
cancer development and progression [4, 7, 14]. The mechanistic underpinnings for
epigenetic dysregulation in promoting cancer are multifaceted with connections to each
hallmark of cancer [15, 16]. For example, a loss of key chromatin regulatory factors that
promote cell differentiation can push cells towards a more stem cell-like phenotype [17,
18]. Emerging evidence has also pointed to connections between epigenetic
dysregulation and tumor immune escape, of importance given the success of
immunotherapies [19, 20]. Given these connections, and the inherent reversibility of
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epigenetic modifications, there is significant interest in targeting epigenetic dysregulation
to treat cancer [15]. Epigenetic regulators make particularly attractive therapeutic targets
given the ability to target the functions of these enzymes pharmacologically using small
molecule inhibitors. Indeed, multiple inhibitors of epigenetic enzymes are being tested in
the clinic and others are already approved for cancer treatments [14]. Increasingly, these
inhibitors are also being tested in combinatorial approaches in an attempt to synergize
the efficacy of approved treatments, such as immunotherapies [21-24]. Collectively,
these data highlight the recent, rapid expansion of epigenetic targeting therapies in
medicine as well as point to their tremendous therapeutic potential in treating cancer in
the coming years.

1.2 Epidermal Biology and Cutaneous Squamous Cell Carcinoma
1.2.1 The structure and organization of the skin
Epigenetic regulation plays a particularly crucial role in self-renewing somatic
epithelia which rely on a constant balance between proliferation and differentiation to
maintain tissue homeostasis [12]. A prime example of this is the epidermis of the skin
which relies on the continuous replacement of its upper layers with new cells, with a
turnover of approximately four weeks in humans [25]. This allows the skin to function as
the body’s external most barrier, protecting internal tissues from damage due to
mechanical stress, physical insults, ultraviolet radiation (UVR), pathogens, or water loss
[26]. The epidermal cycle of renewal is achieved through the activity of proliferative stem
cells which reside in the basal, innermost layer of the epidermis. As these cells divide,
daughter cells may exit the basal layer and will initiate a complex, stepwise
differentiation program as they migrate toward the surface of the skin where they
ultimately die [27]. This results in multiple, progressively differentiated epidermal layers
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which, from innermost to outermost include: 1) the basal layer 2) the spinous layer 3) the
granular layer and 4) the stratum corneum. Each layer has different features required for
the proper function of the skin and are characterized by specific proteins unique to that
differentiation state [12, 26-29]. In addition to containing the proliferative cells, the basal
layer is distinct for its assembly of an extracellular matrix it attaches to at the dermis and
enrichment for keratins 5 and 14 (K5/K14) [27]. In the spinous layer, these basal
components are disintegrated, and a unique transcriptional profile drives the expression
of desmosomes and keratins 1 and 10 (K1/K10) which anchor these cells together to
form a tightly bound network. Cells in the granular layer undergo vast changes,
simultaneously producing lipid rich lamellar granules (LG) and structural proteins, such
as involucrin (IVL), while disintegrating their nuclei and cytoplasmic organelles [28].
These cells will then release LG contents into the extracellular space and undergo nonapoptotic programmed cell death commonly referred to as cornification [28]. The
remaining matrix of dead cells and lipids forms the stratum corneum and is enriched with
the interfilamentous protein filaggrin (FLG). The precise coordination of each of these
steps is critical to the formation of the proper epidermal barrier and dysregulated
differentiation is a common feature of skin disease [29]. Intriguingly, the mode of cell
death utilized during keratinocyte terminal differentiation is unknown and remains a
fundamental outstanding question in the field of dermatology [26]. Given the widespread
prevalence of skin disease, including cancer, better characterization of this process is
clinically important.
1.2.2 Cutaneous squamous cell carcinoma
Ultimately, the protective capacities of the skin described above are not limitless,
and chronic environmental damage can result in skin cancer [30]. Increased recreational
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sun exposure, combined with the aging of the U.S. population, is leading to an epidemic
of cutaneous neoplasia [31, 32]. Keratinocyte cancers (KCs), consisting of cutaneous
squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), are the two most
common of all human malignancies and collectively outnumber all other cancers
combined [33]. While BCCs are typically thought to outnumber cSCCs, recent Medicare
claims data in the U.S. suggest that they are equally common [32]. Consistently, the
incidence of cSCC, has increased over 200% in the last three decades [34].
Furthermore, the premalignant neoplasms that precede the development of cSCC,
known as actinic keratoses (AKs), account for over 10% of dermatology visits, have a
prevalence of almost 40 million, and annual costs of over 1 USD billion (U.S.D.) [35].
Collectively, these data highlight the enormity of the public health and economic problem
that cSCCs pose, and the need to develop better prevention and treatment strategies.
Current therapies for primary cSCC consist of standard local excision and Mohs
micrographic surgery (MMS) for regions where tissue conservation is important (such as
the head or neck), all with 4–6-mm margins. MMS is performed in cases of high-risk
cSCC and in regions of limited tissue [36]. Other destructive methods, such as
electrodesiccation and curettage, are employed for low-risk cSCC. Scarring and
disfigurement can, therefore, be quite common, underscoring the potential benefit of
effective topical therapies. While topical therapies are also commonly utilized in the
treatment of AKs and early cSCC limited to the epidermal layer of the skin, frequently
referred to as squamous cell carcinoma in-situ (SCCis), they are limited by either a lack
of efficacy or deleterious side effects that frequently hinder use. These include the
antimetabolite 5-fluoruracil (5-FU), topical retinoids, and immunomodulators such as
imiquimod, [37]. While 5-FU demonstrates the best efficacy [38], its use is particularly
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restricted by common and frequently severe localized skin reactions. Indeed, given
these limitations, there remains a need for better topical therapies that may exert both a
direct and local ‘field effect’ phenomenon to treat both visible and subclinical lesions [39].
More aggressive treatment is employed for advanced and metastatic cSCC. For
localized lymph node metastases, surgery followed by adjuvant radiation and/or
systemic therapy is recommended [36]. Patients with distant metastases typically have
received cisplatin and/or systemic 5-FU chemotherapies, though epidermal growth factor
receptor inhibitors such as cetuximab and panitumumab have also demonstrated some
efficacy. Following the approval of pembrolizumab for patients with advanced head and
neck SCC, emerging studies have looked at immunotherapy approaches for cSCC.
Notably, the PD-1 inhibitor, cepilumab, was recently discovered to demonstrate some
response for metastatic cSCC [40]. In all of these cases, treatments are effective in less
than half of patients and are associated with numerous side effects, highlighting the
potential space, and continued need for, new and novel therapies.
Recent genome sequencing efforts have been pivotal in understanding the
genetic basis of cSCC. Within these studies, chromatin and histone modifiers are
commonly among the most mutated genes in cSCC [41, 42]. Similar pan-cancer studies
have extended these observations to SCC as a whole, which together form a genetically
and histologically unified group of diseases [43-46]. SCCs can occur in various tissues
including the skin, nasal cavity, oropharynx, esophagus, and lung, together accounting
for over 10% of all cancer deaths [47]. Notably, SCC development is closely linked to
perturbations in squamous cell lineage commitment and differentiation, biological
processes commonly regulated by epigenetic mechanisms [45]. Collectively, this
provides significant rationale for understanding how epigenetic dysregulation may drive
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tumorigenesis in both cSCC and SCCs as a whole. Given the incredible accessibility of
the skin, studying how epigenetic mutations promote cSCC has the unique, added
advantage of providing insights into other, often difficult to study SCCs.

1.3 The MLL4-LSD1-H3K4 methylation axis
1.3.1 Physiological and tumor suppressive functions of MLL4
Consistent with the idea that epigenetic disruption may promote cSCC, the
histone modifiers MLL4 (KMT2D) and MLL3 (KMT2C) are two of the most commonly
mutated genes in cSCC (>50% of cases) [41, 42]. MLL4/3 are paralogous histone
methyltransferase responsible for monomethylation of histone H3 lysine 4 (H3K4me1).
This epigenetic mark poises gene enhancers for activation and transcription factor
binding and consequently is associated with transcriptional activation [48-50]. In addition
to its catalytic role, MLL4 is required for recruitment of CBP/p300, which acetylates
H3K27 at enhancers resulting in their activation during changes in cellular fate [51, 52].
Recent work has attempted to dissect the importance of MLL4/3 catalytic vs
noncatalytic mechanisms to the regulatory roles of these proteins. For example, while
complete deletion of MLL4/3 in mESCs extensively alters enhancer RNA synthesis and
gene expression, the selective inactivation of their catalytic domains displays surprisingly
minor effects on these functions [53]. Supporting these findings, complete deletion of the
Drosophila MLL4/3 homolog Trr is embryonic lethal, while catalytically inactive Trr
produces no overt phenotype under homeostasis [54]. However, in the setting of
environmental stress catalytically inactivating Trr does have phenotypic consequences.
This observation provoked the hypothesis that perhaps Mll4/3-dependent H3K4me1 is
most essential while fine tuning transcription, particularly during stress responses. In line
with this, a unique epigenetic crosstalk has been observed by which p300 stimulates
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MLL4-mediated H3K4me1 at enhancers to boost gene transcription [55]. This
establishes a potential epigenetic feedforward loop between these enzymes, by which
interplay between H3K4me1 and H3K27ac may fine-tune enhancer activity. Further,
others have found that MLL4/3-dependent H3K4me1 is required for establishing
enhancer promotor looping at MLL4/3 enhancers as well as the recruitment of cohesin
and the BAF (SWI/SNF) remodeling complex at these sites [56, 57]. Collectively, these
data provide compelling evidence that MLL4/3 have critical noncatalytic functions critical
for their gene regulatory effects, but also roles that are clearly optimized by their
catalysis of H3K4me1.
Ultimately, through both their catalytic and noncatalytic roles, MLL4/3 are master
regulators of gene enhancers and consequently, transcription. These functions make
these enzymes essential genes in both mice and humans. Whole-body deletion of MLL4
is embryonic lethal at day 9.5 in mice and its mutation in humans plays causative roles in
the developmental disorder Kabuki syndrome [50, 58]. Several studies have identified
that MLL4/3 may be particularly important in promoting differentiation. Indeed, their loss
impairs differentiation in adipocytes, myocytes, and keratinocytes due to disrupted gene
expression programs and enhancer regulation [50, 59]. It is perhaps not surprising then
that MLL4/3 are two of the most frequently mutated genes across all human cancer
where an impaired ability to properly differentiate can support tumor proliferation [60-64].
Consistent with this, MLL4 loss in lymphoma induces differentiation blockade which
promotes tumorigenesis [65]. Notably, mutations in MLL4 have been associated with
both early clone formation in normal epithelial tissues [66-68], as well as with aggressive
and metastatic forms of cSCC. Despite the high incidence of MLL4/3 mutations in
epithelial tissues, their role in clonal expansion in human skin, and established genetic
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and enhancer regulatory functions, little is understood about how these enzymes may
mediate tumor suppression in the skin.
1.3.2 Physiological and oncogenic functions of LSD1
Opposing the function of MLL4/3, the chromatin modifier LSD1 (KDM1A) is a
histone lysine demethylase. Since its discovery just over 15 years ago, LSD1 has made
landmark changes to our understanding of histone methylation during basic biological
processes as well as cancer. Indeed, histone methylation was originally considered to be
an irreversible process until the identification of LSD1. This provided the first irrefutable
evidence that histone methylation is dynamic and catalyzed the discovery of the over
~20 known histone demethylases today. Consequently, LSD1 is an extremely wellinvestigated protein among epigenetic regulators and has had numerous reviews written
discussing its biology [69-72].
LSD1 plays key roles during numerous biological processes across many tissues
during mammalian development, including stem cell maintenance, differentiation,
metabolism, and epithelial- to-mesenchymal transition (EMT) [73-77]. These diverse
functions are frequently context-specific and primarily mediated through LSD1
association with unique binding partners that alter LSD1 substrate specificity, protein
complex incorporation, and genomic localization. Consequently, LSD1 functions in
various ways acting via: (1) transcriptional repression by removing mono- and dimethyl
groups from histone 3 lysine 4 (H3 K4) [78]; (2) transcriptional activation by removing
repressive methylation marks on H3 lysine 9 (H3K9) in a small number of contexts [7982]; (3) non-histone demethylation to regulate proteins such as p53, DNMT1, E2F1,
STAT3, HIF1α, and MYPT1 [75, 83-86]; and, more recently, (4) non-catalytic functions,
for example, altering the stabilization of interacting partners including the protein FBXW7

10

[87]. Given all these functions, it is perhaps unsurprising that knockout of LSD1 in mice
is lethal at embryonic day 6 suggesting this protein plays a key role during development
[75, 77]. A central function of LSD1 across many tissues is the maintenance of stem cell
or progenitor-like states [88]. In undifferentiated embryonic stem cells, LSD1 is highly
expressed and represses the expression of lineage-specific developmental programs
[89]. LSD1 plays a similar role and is also required for proper differentiation in myocytes,
neurons, adipocytes, and hematopoietic progenitors.
In addition to directing normal cellular functions, LSD1 is crucial to many
oncogenic processes in cancer. In acute myeloid leukemia (AML), LSD1 is frequently
overexpressed and associated with poor prognosis in patients. Mouse models of AML
have revealed that LSD1 is required for disease development and functions to maintain
the stem cell progenitor state of leukemia cells. Inhibiting LSD1 in AML mouse models
and cell lines through genetic deletion or use of pharmacological inhibitors impairs
proliferation and increases differentiation and apoptosis [90, 91]. These findings have
advanced to clinical trials where multiple LSD1 inhibitors are currently being tested for
treating AML. LSD1 has also been studied in the context of solid tumors, for example, in
breast and prostate cancers. Like hematological malignancies, LSD1 overexpression
promotes cellular proliferation and is associated with aggressive phenotypes in these
cancers. However, these studies also highlight an additional oncogenic function of LSD1
showing that it plays a role in mediating EMT and cancer cell migration and invasion [79,
92-95]. Consistently, studies show that LSD1 binds with the Snail/Slug family
transcription factors which promote cancer cell metastasis and LSD1 inhibitors can
disrupt these interactions to block cancer cell invasion [96, 97]. It has also been recently
discovered that LSD1 is key for suppressing endogenous double-stranded RNA
(dsRNA) levels and interferon responses in tumor cells. Inhibiting LSD1 leads to
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improved antitumor immune responses and causes refractory mouse melanoma tumors
to respond to anti-PD-1 therapy [21]. This opens a wide range of new potential
therapeutic applications for LSD1 inhibitors given the recent successes of
immunotherapies. Collectively, these data demonstrate the multifaceted oncogenic
functions of LSD1 in cancer and highlight its status as an attractive therapeutic target.
Interestingly, it has been found that human cSCC cell lines are sensitive to LSD1
inhibitors alone or in combination with HDAC inhibitors as measured using proliferation
assays. Notably, cSCC cell lines were most sensitive to a single molecule, dual-action
LSD1/HDAC inhibitor. When tested in primary human keratinocytes, this dual-action
inhibitor was also better tolerated than single-agent LSD1 inhibitors [98]. This highlights
the sensitivity of human cSCC cell lines to LSD1 inhibition and is an effect that may be
exacerbated by comprehensively targeting epigenetic complexes containing LSD1 and
HDACs. These data point to the need to understand how LSD1 may promote cSCC
tumorigenesis as well as the basic biological roles of this protein in the epidermis.
Indeed, how LSD1 functions in normal epithelial tissues or other squamous cell
carcinomas (SCCs) remains a major gap in knowledge. This is particularly surprising
given that LSD1 is commonly overexpressed and known to associate with poor
prognosis in SCCs of the esophagus [99, 100], oral mucosa [101, 102], and lung [103].
Answering these questions is also important given the high rates of loss-functionmutations of the opposing methyltransferases MLL4/3 in these tumors. These genetic
and clinical data support the idea that LSD1 may be a promising therapeutic target in
cSCC and warrant further study of how MLL4/3-LSD1 epigenetic dysregulation promotes
cSCC.
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1.3.3 Pharmacologically targeting LSD1
The demethylase activity of LSD1 lies within its enzymatic FAD-dependent amine
oxidase-like domain which shares structural homology with other flavin-containing
monoamine oxidase (MAO) enzymes. Because of this, the first attempts to inhibit LSD1
activity utilized existing MAO inhibitors such as tranylcypromine (TCP) which is used
clinically for treating depression [72, 104]. TCP sufficiently inhibits LSD1 activity by
forming a covalent adduct with FAD in the active site of LSD1 to irreversibly inhibit
enzyme function [105]. However, TCP has less than desirable specificity and potency for
use in targeting LSD1 therapeutically, resulting in the subsequent development of
numerous, highly specific LSD1 inhibitors. These can be broadly classified into two
categories including inhibitors that, like TCP, work via an irreversible mechanism of
action or those that reversibly inhibit LSD1. Several LSD1 inhibitors are currently
undergoing clinical trial either for applications in cancer or other diseases including: (1)
TCP; (2) ORY-1001 [106]; (3) IMG-7289; (4) INCB059872; (5) ORY-2001; and (6) CC90011. A very recent, detailed description of each of these drugs and their advances in
the clinic has been extensively reviewed [107]. Most of these inhibitors (2–5) are TCP
derivatives and contain a shared primary molecular scaffold that irreversibly inhibits
LSD1 by forming covalent FAD adducts. However, as mentioned, relative to TCP they
have better specificity and potency attributed to unique chemical modifications added to
the TCP-scaffold phenyl ring and amine group [107]. CC-90011 (6, above) is the only
reversible LSD1 inhibitor to reach the clinic but highlights the potential of this broad
category of compounds which attempt to curtail any enduring off-target effects that
irreversible inhibitors can suffer from [108]. Generally, reversible inhibitors, including CC90011, have distinct molecular structures and mechanisms of action from TCP. For
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example, the reversible LSD1 inhibitor SP2509 is thought to function by reducing LSD1
binding with the Co-REST complex to hinder its demethylase functions [109]. Among the
LSD1 inhibitors being clinically tested, ORY-1001 is perhaps best described and has
shown to be both highly selective and potent, inhibiting LSD1 activity with an IC50 of
less than 20 nM [106]. Phase IIa clinical trials for ORY-1001 are currently underway for
its use in AML. Despite the exciting potential of these clinical developments, three phase
I clinical trials using the LSD1 inhibitor GSK-2879552, a TCP-analog that works
irreversibly, have recently been terminated because of unfavorable risk benefit tied to
drug side effects. This brings attention to the drawbacks of the systemic use of broadbased epigenetic inhibitors and the need for advances in the delivery strategies of these
drugs to their target sites [110]. Although potentially effective as monotherapies, LSD1
inhibitors likely hold the most promising potential through their use in combination
therapy. Indeed, it is well known that epigenetic drugs often produce synergistic effects
when used in combination with other anti-cancer therapies [111]. As mentioned, one
exciting combination that likely holds tremendous therapeutic potential is that of LSD1
inhibitors with PD-L1 blockade to improve anti-tumor immune responses [21]. In addition
to this, others have observed synergistic effects of LSD1 inhibitors when combined with
other known epigenetic inhibitors such as azacytidine, a clinically approved DNMT1
inhibitor, or histone deacetylase (HDAC) inhibitors [106]. Interestingly, others have taken
this strategy even further by developing single molecule, dual-action LSD1/HDAC
inhibitors to comprehensively target these epigenetic enzyme complexes [98]. The
promising anti-tumor properties of such compounds, and added benefits of a single
molecule approach clinically, speak to the potential of this strategy and is an important
consideration when considering LSD1 as a therapeutic target. Finally, LSD1 inhibitors
are able to sensitize non-acute promyelocytic leukemias to treatment with all-trans-
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retinoic acid, a strategy that is actively being tested in clinical trials [112]. Many existing
LSD1 inhibitors, particularly TCP-analogs, were primarily designed to target the catalytic
activity of this protein. However, when considering LSD1 as a pharmacological target it
is also necessary to acknowledge its emerging noncatalytic roles [87, 113]. Indeed, an
abundance of recent findings have demonstrated the array of critical, noncatalytic
functions of histone modifiers during development and disease [1]. Interestingly, there
have been several reports that existing LSD1 inhibitors both inhibit LSD1 catalytic
activity and prevent its binding to genomic targets [113, 114]. This raises the question of
whether the effects of LSD1 inhibitors are completely tied to inhibiting LSD1 catalytic
activity or if the disruption of noncatalytic functions of LSD1 may play a role in their antitumorigenic effects. Future work to characterize the noncatalytic mechanisms of LSD1
and more directly inhibit these functions using pharmacological approaches will likely
expand the already enormous therapeutic potential of targeting this protein.

1.4 Thesis objectives and roadmap for subsequent chapters
Collectively, these findings can be summarized into three general observations:
1) Epigenetic mechanisms regulate chromatin structure, and therefore gene expression,
to direct dynamic biological processes, but become hijacked to promote tumorigenesis,
making epigenetic enzymes attractive therapeutic targets in cancer. 2) The skin
achieves its function as a barrier through precise coordination of differentiation and cell
death, disruption of which can result in cutaneous squamous cell carcinoma, one of the
most common cancers worldwide in need of better therapeutic options. 3) The MLL4/3LSD1 epigenetic axis regulates enhancer function and gene expression and is
commonly dysregulated during carcinogenesis, but whose functions during epidermal
differentiation or cancer are unknown despite prevalent MLL4/3 loss of function
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mutations in cSCC. These observations lay the groundwork for the overarching objective
of this thesis which is to determine the roles of the MLL4/3-LSD1 epigenetic axis during
epidermal differentiation and carcinogenesis with the ultimate goal of identifying potential
new therapeutic targets in cSCC.
To this end, in chapter 2 we examine the consequence of loss of Mll4 and Mll3 in
the epidermis in mice in vivo. We identify a critical role for Mll4 in the promotion of
epidermal differentiation and ferroptosis opening the possibility of targeting this
dysregulation to treat cSCC. Further, our data uncover a potentially fundamental role for
ferroptosis during terminal differentiation and tumor suppression in the epidermis. In
chapter 3, we study the effect of pharmacological inhibition of LSD1 in epidermal cells in
vitro. Here, we find that LSD1 regulates SNAI2-repressed fate-determining transcription
factors that promote differentiation and find that LSD1 inhibitors may represses
squamous carcinogenesis using a 3D organotypic cSCC model. Finally, in chapter 4 we
discuss the summary of impact and broader implications of this work as well as key
unanswered questions and potential future directions to address these gaps in
knowledge.
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Chapter 2: MLL4 mediates epidermal differentiation and tumor suppression
via ferroptosis
This chapter includes work adapted from a previously published manuscript in Science
Advances [115].
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2.1 Introduction
Epigenetic dysregulation is a “hallmark” of human cancer [116], with almost half
of all human cancers bearing mutations in epigenetic regulators. Squamous cell
carcinomas (SCCs) occur on a variety of epithelial surface tissues and harbor the
highest rates of mutations in chromatin-modifying enzymes among cancers [44]. The
epigenetic regulator MLL4 (KMT2D) is considered an essential gene in both human and
mice [50, 117] and is one of the most frequently mutated genes across all of human
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cancer [60-64]. Notably, mutations in MLL4 have been associated with both early clone
formation in normal epithelial tissues [66-68], as well as with aggressive and metastatic
forms of cutaneous SCC (cSCC) [41, 42, 118], the second most common of all human
malignancies [33]. The emerging picture, from both these and other studies [61, 62],
suggests that MLL4 typically accumulates loss of function mutations that impair its ability
to suppress both the initiation and progression of cancer. Despite this, while previous
work from our laboratory has identified a critical role for MLL4 in epidermal gene
regulation [59], the mechanisms behind MLL4-mediated tumor suppression in the skin is
virtually unknown. Given the pervasive nature of keratinocyte cancers (i.e., cSCC and
basal cell carcinoma, which collectively outnumber all other human cancers) [33], as well
as MLL4 mutations in this tissue, understanding the underlying mechanisms at play
offers the potential for identifying previously unknown therapeutic targets.

2.2 Results
2.2.1 Mll4 deficiency in the epidermis promotes altered differentiation and proliferation
To begin to address this knowledge gap, we created mice with epidermal-specific
deletions of Mll4, as the total body knockout of Mll4 is embryonic lethal at day 9.5 [50].
We used a previously described conditional knockout of Mll4 in which the catalytic SET
domain is flanked by two floxP sites (exons 50 and 51) and whereby Cre-mediated
deletion of the floxed catalytic SET domain destabilizes the protein and results in tissuespecific deletion of Mll4 [119]. We crossed this genetic model with keratin 14 Cre (Krt14Cre)–expressing mice to generate mice with epidermal deletions of Mll4 (Krt14-Cre;
Mll4fl/fl or “Mll4-eKO”) (fig. S1A). Mll4-eKO mice were born in the expected Mendelian
ratios (fig. S1B) with no visible differences from littermate controls during the first week
of life. However, at approximately 21 days after birth, Mll4-eKO mice displayed a notable

18

cutaneous phenotype marked by visibly red, scaly skin with scattered regions of
substantial hair thinning (Fig. 1A). In addition to this, Mll4-eKO mice were visibly smaller
(Fig. 1A) and weighed 40% less than controls (fig. S1C). This weight difference was
consistent across genders (Fig. 1B). At the histological level, Mll4-eKO mice displayed
multiple consistent abnormalities in the epidermis as revealed by hematoxylin and eosin
(H&E) staining, including overall tissue disorganization and scattered regions of notable
epidermal hyperplasia and hyperkeratosis (Fig. 1C). These regions of hyperplasia and
hyperkeratosis were notable for both the presence of atypical keratinocytes with large
nuclei and increased numbers of mitotic cells (Fig. 1C, inset), all features commonly
observed in the precancerous form of cSCC in humans known as actinic keratoses. As
Krt14 is also expressed in the oral and esophageal epithelia, we also examined these
tissues. Similar to the epidermis, we observed scattered, albeit more rare regions of,
epithelial hyperplasia in the oral epithelium of the tongue (fig. S1D), while the
esophageal epithelium appeared largely unremarkable (fig. S1E).
In the skin, Mll4-eKO mice also presented with sporadic improperly formed hair
follicles that resulted in the formation of cystlike structures (Fig. 1C), consistent with the
observed hair thinning and regions of alopecia seen in these mice (Fig. 1A). Given Mll4’s
role in catalyzing histone H3 lysine 4 monomethylation (H3K4me1), we examined the
global levels of this modification that marks gene enhancers by immunofluorescence (IF)
and observed significantly reduced levels (Fig. 1D). These features were not observed in
littermate controls, which had a histologically normal epidermis.
Given these histological anomalies, we next assessed the various layers of the
epidermis that correspond with progressive differentiation states. As expected, control
samples had a single layer of Krt14-positive staining cells marking the proliferative basal
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stem cell layer and a distinct, more terminally differentiated Krt10-staining spinous layer
(Fig. 1E). In contrast, Mll4-eKO mice displayed a multilayered, expanded Krt14 layer
suggestive of a potential failure of upward differentiation of the basal stem cells (Fig.
1E). Further, the expanded Krt14 layers in the epidermis of Mll4-eKO mice commonly
contained dual Krt14- and Krt10-positive staining keratinocytes further suggesting a
state of dysfunctional epidermal differentiation (Fig. 1E). As increased inflammation from
barrier disruption can drive epidermal hyperplasia in different contexts [120], we
investigated levels of inflammation using both H&E and CD3 T cell staining. In both
cases, Mll4-eKO did not demonstrate any difference in the amount or numbers of
immune cells (Fig. 1, F and G), suggesting that the significant hyperplasia we observed
was not just secondary to increased inflammation.
To observe how Mll4 loss affects epidermal homeostasis and differentiation over
time, we aged Mll4-eKO mice for at least 1 year and some for up to 2 years. The
epidermal phenotype persisted in Mll4-eKO and appeared to worsen with age, including
progression of both the grossly visible hair loss and scaly, hyperkeratotic skin (Fig. 1F).
Similarly, at the histological level, the abnormal epidermal phenotype seemed to
progress over time, as Mll4-eKO mice displayed regions of neoplastic proliferation, many
of which appeared to be more infiltrative and consistent with early cSCC lesions in
humans (Fig. 1G). Consistent with this observation, an expanded Krt14/Krt10 dualstaining layer was also observed in these mice (Fig. 1H). Together, these data
demonstrate that Mll4 loss significantly impairs proper epidermal homeostasis and
differentiation in vivo.
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Fig. 1. Mll4 deficiency in the epidermis promotes altered differentiation and neoplastic
proliferation. (A) Representative 3-week-old Mll4-eKO and control mice. (B) Weights of either
male or female 3-week-old Mll4-eKO (red) and control (blue) mice (n = 17 to 19 mice per
genotype, all P < 0.0001). (C) H&E staining of 3-week-old Mll4-eKO and control mice epidermis
(n = 17 to 19 mice per genotype). Scale bars, 200 µM. (D) IF staining of 3-week-old Mll4-eKO and
control mice epidermis for H3K4me1 (green), Krt14 (red), and DAPI (blue) (n = 5 mice per
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genotype). (E) IF staining of 3-week-old Mll4-eKO and control mice epidermis for Krt14 (red),
Krt10 (green), and DAPI (blue) (n = 5 mice per genotype; box denotes zoomed-in section). (F)
Representative 1- to 2-year-old Mll4-eKO and control mice. (G) H&E histological staining of 1- to
2-year-old Mll4-eKO and control mice epidermis (n = 3 mice per genotype). (H) IF staining of 1- to
2-year-old Mll4-eKO and control mice epidermis for Krt14 (red), Krt10 (green), and DAPI (blue) (n
= 3 mice per genotype). Black and white dashed lines delineate the epidermal and dermal
boundary. Scale bars, 100 µM, unless otherwise noted.

2.2.2 Loss of Mll4 leads to a profoundly altered transcriptome characterized by loss of
key genes involved in differentiation and lipid metabolism
To begin to understand the mechanisms behind these changes, we performed
RNA sequencing (RNA-seq) on the epidermis from littermate control and Mll4-eKO mice.
As expected, given Mll4’s critical role in transcriptional regulation, Mll4-eKO mice
demonstrated substantial transcriptional alterations with roughly equal number of
significantly down-regulated and up-regulated genes (Fig. 2A and table S1). Gene
Ontology (GO) analysis of down-regulated genes demonstrated a significant enrichment
of genes involved in lipoxygenase activity and lipid metabolism (Fig. 2B). This was
particularly compelling given the essential role of both of these processes in normal
epidermal homeostasis and barrier formation [121, 122].
In contrast, genes up-regulated in the Mll4-eKO mice were enriched for
numerous genes and GO terms involved in various aspects of fatty acid metabolism,
such as fatty acid synthesis, β- oxidation, and elongation (fig. S2A and table S1). This
was intriguing given that fatty acid metabolism has been implicated in promoting both
metastasis and treatment resistance in cancer [123-126]. Notably, many of these
significantly up-regulated genes have been reported to be involved in driving cancer
invasion and metastasis such as Acat (Soat1), Cd36, Fabp5, Mgll, Scd1, Slc1a5, and
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Slc7a11 [127, 128]. For example, CD36 has been shown to mark metastasis-initiating
cells in oral SCC and targeting it inhibits metastasis in vivo [129].
To examine whether Mll4 might directly regulate these genes, we differentiated
primary normal human epidermal keratinocytes (NHEKs) in vitro and mapped Mll4
binding by chromatin immunoprecipitation sequencing (ChIP-seq). Intersection of Mll4
peaks with genes significantly down-regulated in Mll4-eKO mice demonstrated
substantial overlap (Fig. 2C). These included genes involved in epidermal development,
differentiation, and barrier formation such as the retinoic acid receptor gene, RARG, and
SCNN1A (Fig. 2, D and E) [130, 131]. Notably, the ChIP-seq data demonstrated that the
MLL4 peaks emerged at many of these genes only in the differentiated NHEKs and were
not present in the proliferating, undifferentiated NHEKs (Fig. 2E). Specifically, there were
1389 peaks that were unique to the differentiated state, while only 209 were unique to
the proliferating stem cell state (Fig. 2, B and C, and table S2). Most of the peaks (1870)
were common to both (Fig. 2, B and C, and table S2). Consistent with previous data [59],
motif analysis demonstrated that the top transcription factor motifs for MLL4 binding
enrichment were those for the master epithelial transcription factor, p63, and p53 (fig.
S2D). Western blotting and immunohistochemistry (IHC) confirmed that these gene
expression changes resulted in reduced protein levels for retinoic acid receptor gamma
(RARγ) and sodium channel epithelial 1 subunit alpha (SCNN1A), respectively (Fig. 2, F
and G). Collectively, these data demonstrate that mice lacking Mll4 in the epidermis
display broad gene expression alterations marked by the loss of key genes and
pathways involved in epidermal differentiation and barrier formation consistent with the
significant phenotype observed in Mll4-eKO mice. Furthermore, MLL4 binds directly at
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enhancers near many of these genes during the course of differentiation, indicating a
potentially direct role in activating their expression.

Fig. 2. Loss of Mll4 leads to a profoundly altered transcriptome characterized by a loss of
key genes involved in differentiation and lipid metabolism. (A) Differentially expressed genes
(1618 down-regulated genes and 1687 up-regulated genes) in isolated bulk epidermis of 3-weekold Mll4-eKO and control mice. Dashed line denotes adjusted P value (Padj) of 0.05 (n = 3 to 4
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mice per genotype). (B) GO biological process analysis of Mll4-eKO differentially expressed
down-regulated genes (1618genes). Down-regulated genes driving the top GO term
“lipoxygenase pathway” are highlighted. (C) Intersection of all MLL4-bound region-associated
genes in NHEKs and down-regulated genes in Mll4-eKO mice (255 genes). (D) Left: GO
biological process analysis of the intersection in (D) (255 genes). Right: List of key epidermal
differentiation genes enriched in GO terms from (D) intersection. (E) ChIP-seq for MLL4 in
proliferating or differentiated primary human keratinocytes at key epidermal differentiation
(RARG) and barrier (SCNN1A) genes listed in Fig 2E (n = 2 to 3 per condition). (F) Immunoblot of
Rarg and actin isolated from bulk epidermis of 3-week-old Mll4-eKO and control mice. Molecular
ladder shown to the right of blot (n = 2 mice per genotype). (G) IHC staining of Sccn1a of 3-weekold Mll4-eKO and control mice epidermis (n = 3 mice per genotype. Scale bar, 200 µM). FDR,
false discovery rate; FC, fold change

2.2.3 In contrast to Mll4 loss, Mll3 deficiency leads to modest effects in the epidermis
Similar to MLL4, the related histone methyltransferase, MLL3 (KMT2C), also
catalyzes H3K4me1and is frequently mutated in numerous human cancers, including
SCCs [60-64]. Therefore, we also wanted to investigate the role of MLL3 in epidermal
biology and tumor suppression. To do this, we took a similar approach to generate mice
with epidermal-specific deletions of Mll3 by crossing Krt14-Cre mice with mice carrying
Mll3 alleles with loxP sites flanking a 61–amino acid region of the catalytic SET domain.
Cre-mediated recombination results in deletion of the targeted region (fig. S3A) and
results in destabilization and loss of the full protein [132, 133]. In clear contrast to Mll4eKO mice, mice lacking Mll3 in the epidermis (“Mll3-eKO”) did not display any obvious
phenotypic alterations beyond subtle changes around the eye (Fig. 3A and fig. S3B).
There was no significant change in weight between control and Mll3-eKO mice (Fig. 3B).
Histologically, the Mll3-eKO mice also did not demonstrate significant or consistent
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changes in epidermal thickness or organization (Fig. 3C), and H3K4me1 levels were
only minimally reduced (Fig. 3D). Consistent with these findings, Krt14 and Krt10
staining did not suggest alterations in differentiation dynamics in contrast to Mll4-eKO
mice (Fig. 3E). Last, RNA-seq of Mll3-eKO mice showed that a loss of Mll3 in the
epidermis only led to modest alterations in gene expression (Fig. 3F and table S3), with
minimal overlap with those genes altered by Mll4 deficiency (fig. S3C). Together, these
data demonstrated that Mll4 plays a more critical role in epidermal gene regulation,
homeostasis, and differentiation than Mll3.
To determine whether Mll3 may compensate on some level for the loss of Mll4 in
the epidermis or whether it was completely dispensable even in the setting of Mll4
deficiency, we attempted to generate mice lacking both Mll3 and Mll4 in the epidermis.
Here, we observed that mice lacking Mll4 and one copy of Mll3 were even more severely
affected than mice lacking just Mll4, suggesting that Mll3 does perform some
compensatory functions for Mll4 in its absence. These Krt14-Cre(+); Mll4fl/fl; Mll3+/fl
mice displayed markedly wrinkled, scaly skin with sparse hair (Fig. 3G). Notably, these
mice were significantly more affected than mice lacking all Mll3 and one copy of Mll4
(Krt14-Cre(+); Mll4fl/+; Mll3fl/fl) (Fig. 3H). At the histological level, Krt14-Cre(+); Mll4fl/fl;
Mll3+/fl mice presented with an even more thickened epidermis and expanded epidermis
than mice lacking only Mll4 (Mll4-eKO) (Fig. 3I and fig. S3D). In contrast, Krt14-Cre(+);
Mll4fl/+; Mll3fl/fl mice (fig. S3, E to G) appeared less affected than both Krt14-Cre(+);
Mll4fl/fl; Mll3+/fl mice and Mll4-eKO mice (Fig. 3, J to L). We found that we were unable
to generate any live mice lacking both Mll3 and Mll4, suggesting that at least one copy of
these two related enzymes is required for epidermal development (fig. S3H).
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Fig. 3. In contrast to Mll4 loss, Mll3 deficiency leads to modest effects in the epidermis. (A)
Representative 3-week-old Mll3-eKO and control mice. (B) Weights of either male or female 3week-old Mll3-eKO (red) and control (blue) mice (n = 9 to 16 mice per genotype, P = 0.49). NS,
not significant. (C to E) Comparison of 3-week-old Mll3-eKO and control mice epidermis by (C)
H&E staining, (D) IF staining of H3K4me1 (green), Krt14 (red), and DAPI (blue) or (E) IF staining
of Krt14 (red), Krt10 (green), and DAPI (blue) (n = 3 mice per genotype). (F) Differentially
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expressed genes (55 down-regulated genes and 37 up-regulated genes) in isolated bulk
epidermis of Mll3-eKO and control mice. Dashed line denotes adjusted P value of 0.05 (n = 6
mice per genotype). (G) Representative 1-week-old Krt14-Cre(+); Mll4fl/fl; Mll3+/fl mouse alone
(yellow asterisk) (left) or beside a littermate control (right). (H) Littermate sibling Krt14-Cre(+);
Mll4fl/+; Mll3fl/fl (top) and Krt14-Cre; Mll4fl/fl; Mll3+/fl (bottom) mice compared. (I) H&E staining of
a Krt14-Cre(+); Mll4fl/fl; Mll3+/fl mouse epidermis (n = 3 mice per genotype). (J) Littermate sibling
Krt14-Cre(+); Mll4fl/+; Mll3fl/fl and Krt14-Cre(+); Mll4fl/fl; Mll3+/fl mice compared by (J) H&E
histological staining of the epidermis, and (K) IF staining for Krt14 (red), Krt10 (green), and DAPI
(blue) (n = 3 mice per genotype). (M and N) Comparison of the epidermis of vehicle and
tamoxifen-treated Krt14-CreERtam; Mll4fl/fl; Mll3fl/fl mice by (M) H&;E staining or (N) IF staining
of Krt14 (red), Krt10 (green), and DAPI (blue) (n = 2 mice per group, one vehicle control and one
genotype control). Black and white dashed lines delineate the epidermal and dermal boundary.
Scale bars, 100 µM, unless otherwise noted.

2.2.3 Continued…
To test this further, we created a tamoxifen-inducible line of these mice using a Krt14CreERtam system. Using this approach, we demonstrated that deletion of both Mll3 and
Mll4 in the adult epidermis recapitulated several of the phenotypic manifestations of
embryonic loss of Mll4 and/or Mll3 (Fig. 3, M and N). In contrast to the constitutive
model, these data demonstrated that complete deletion of both enzymes in the adult
epidermis was compatible with life. Collectively, these observations supported the
conclusions that Mll4 is indeed the more critical H3K4 monomethylase in the epidermis
and that at least one copy of Mll3 or Mll4 is required for epidermal development and
viability.
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2.2.4 Mll4 deficiency impairs ferroptosis via rewired gene expression
To begin to explain the more severe phenotype observed with Mll4 loss in
comparison to Mll3, we took advantage of the substantially different transcriptional
profiles that these mice displayed and the fact that the changes appeared to reflect the
observed unique phenotypic manifestations. In particular, the most notable difference
observed in the Mll4-eKO mice was the significant loss of expression of key genes
involved in lipoxygenase activity such as Alox12, Alox12b, and Aloxe3 (Fig. 2D). While
lipoxygenases are well established as key enzymes during the process of epidermal
differentiation [122], we were particularly intrigued by their emerging role in the relatively
recently discovered form of programmed tumor suppressive cell death known as
ferroptosis that is characterized by lipid peroxidation (Fig. 4A) [134-136]. For example,
Arachidonate 12-Lipoxygenase, 12S Type (Alox12) is required for p53-mediated tumor
suppression via ferroptosis [134]. Many human cancers are noted to have a loss of one
copy of ALOX12 on chromosome 17p [137, 138], and variants in ALOX12 have also
been associated with human SCCs [139]. In addition to the loss of these key
lipoxygenase enzymes, two of the key genes that suppress ferroptosis through the
elimination of lipid peroxides, Slc7a11 and Gpx4 [134-136, 140], were concomitantly
significantly up-regulated in the Mll4-eKO mice (Fig. 4A). Furthermore, among the upregulated fatty acid metabolism genes we identified in the Mll4-eKO mice (Fig. 2A), the
gene stearoyl coenzyme A (CoA) desaturase-1 (Scd1), the rate-limiting enzyme
monounsaturated fatty acid synthesis, has been shown to both promote cancerous
invasion and protect against ferroptosis [141, 142].
Given these changes, we first verified Alox12 loss at the protein level in Mll4eKO, but not Mll3-eKO mice (Fig. 4B). We then used a marker of lipid peroxidation and
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ferroptosis, 4-hydroxynoneal (4-HNE) [136, 143], to assess the impact that loss of Mll4
might have. Notably, we observed a marked reduction in 4-HNE staining in Mll4-eKO
mice (Fig. 4C), suggesting that a potentially significant reduction in Alox-mediated
ferroptosis might occur in the setting of Mll4 deficiency. More speculatively, these data
provoked the hypothesis that ferroptosis may actually play a critical role in the promotion
of epidermal differentiation. The precise mechanism by which keratinocytes enucleate
and undergo programmed cell death during terminal differentiation is poorly understood.
Therefore, we stained human skin samples to assess how the ferroptosis marker, 4HNE, may appear. We observed a clear progressive increase in staining intensity as
cells progressed toward terminal differentiation, with the highest levels of staining
observed in the highly metabolically active stratum granulosum (Fig. 4D), precisely
where keratinocytes make the transition to becoming enucleated and forming the
stratum corneum where they ultimately slough off the skin. Given the iron-dependent
nature of both ferroptosis and the lipoxygenase enzymes, we next tested the effects of
depleting iron on epidermal differentiation and stratification by treating engineered threedimensional (3D) human skin organoids [144] with the iron chelator, deferiprone (DFP).
DFP treatment markedly disrupted normal epidermal differentiation and stratification
throughout the epidermis (Fig. 4E). This was characterized by notable clearing of
cytoplasm in the spinous layers, a complete loss of granular layers and keratohyalin
granules, and parakeratosis (Fig. 4E). Collectively, these results suggest that ferroptosis
may play a critical role in the promotion of epidermal differentiation and that loss of Mll4
function impairs this process to result in precancerous neoplasms in the epidermis.
In support of these observations, data from the Human Protein Atlas [145]
confirmed the enrichment of anti-ferroptotic regulators like GPX4, SCD1, and GCH1 in
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the proliferative basal stem cell layer, while pro-ferroptotic proteins like Alox12 were
enriched in the stratum granulosum where the highest levels of 4-HNE were observed
(Fig. 4F). In addition, data from The Cancer Genome Atlas (TCGA) [60, 64] showed that
lower expression of MLL4 was significantly associated with both lower expression of
ALOX12 and higher expression of GPX4 in human head and neck SCC as well as
bladder cancer (Fig. 4G). In support of a direct role for MLL4 in promoting the expression
of these lipoxygenase genes, ChIP-seq demonstrated that MLL4 binds at potential
regulatory elements and enhancers adjacent to these Alox-family genes (Fig. 4H).
Furthermore, in addition to our previous data showing that MLL4 interacts with the
transcription factor, p63 [59, 146], we identified that MLL4 also interacts with p53 (Fig.
4I). Both p53 and p63 have been shown to induce the expression of Alox12 to promote
both epidermal differentiation [147] and tumor suppression [134, 148], respectively. This
is also consistent with our ChIP-seq motif analysis showing that the main transcription
factor binding motifs of MLL4 are p63/p53 sites (fig. S2D). Together, these data support
a model whereby Mll4 is critical for the activation of key lipoxygenase genes such as
Alox12 to promote both epidermal differentiation and barrier formation and, in turn, tumor
suppression via ferroptosis (Fig. 4A). Beyond this direct regulation of lipoxygenase
genes, the aberrant up-regulation of ferroptosis-suppressing genes such as Gpx4,
Slc7a11 and Scd1 in Mll4-eKO mice supports a potentially lipogenic and ferroptosisresistant state that confers a cellular advantage to promote the neoplasms observed in
these mice.
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Fig. 4. Mll4 deficiency impairs ferroptosis via rewired gene expression. (A) Schematic
demonstrating that knockout of Mll4 results in lost expression of pro-ferroptosis genes (Alox12,
Alox12b, and Aloxe3) and up-regulation of key anti-ferroptosis genes (Slc7a11 and Gpx4)
ultimately decreasing cellular lipid peroxides and inhibiting ferroptosis. (B) Immunoblot of Alox12
and actin isolated from bulk epidermis of 3-week-old Mll4-eKO, Mll3-eKO, and control mice.
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Molecular ladder shown to the right of blot (n = 2 mice per genotype). (C) IHC staining of 4-HNE
in 3- to 8-week-old Mll4-eKO and control mice epidermis (n = 5 mice per genotype). (D) IHC
staining of 4-HNE in human epidermis (n = 4 patient samples). Dashed line indicates epidermal
and dermal boundary. (E) 3D human skin organoids treated with 1 mM DFP display marked
alterations in epidermal differentiation including a complete loss of the granular layer and
parakeratosis in comparison to DMSO-treated controls. (F) IHC staining of anti-ferroptosis
(GPX4, SCD, and GCH1) or pro-ferroptosis (ALOX12) proteins in human epidermis obtained from
the Human Protein Atlas. Scale bars, 200 µM. (G) Comparison of GPX4 and ALOX12 expression
in the lowest one-fourth and highest one-fourth of MLL4-expressing tumors in 515 human head
and neck SCCs (left) or 411 human bladder cancers (right) obtained from TCGA. All P < 0.05. (H)
ChIP-seq for MLL4 in proliferating or calcium differentiated human keratinocytes at the Alox
family genes (n = 2 to 3 per condition) (I) Co-IP of MLL4, followed by immunoblotting of p53 in
human keratinocytes (n = 3). Scale bar, 100 µM, unless otherwise noted. IgG, immunoglobulin G.

2.3 Discussion
In summary, our results offer unique insight into the primary importance of MLL4
as compared to MLL3 in the skin epidermis. As MLL4 (KMT2D) loss of function
mutations are among the most common events in human cancer, the results presented
here offer a novel mechanism by which these mutations may promote both the initiation
and progression of cancer, particularly in the setting of keratinocyte cancers, which
collectively outnumber all other human malignancies [33]. Given the ability to
pharmacologically induce ferroptosis through inhibitors of targets such as GPX4 or
SLC7A11 [135, 136], these data suggest a potentially new therapeutic strategy for
treating epithelial cancers like SCC, particularly in the setting of MLL4 mutations. In
addition, in the context of recent evidence demonstrating that drugs that induce
ferroptosis can also operate synergistically with immunotherapies [136, 149], there may
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exist even more potential uses when used in combination. More generally, as these
results implicate ferroptosis in the general process of epidermal differentiation and skin
homeostasis, it suggests that future studies may uncover a role for dysregulated
ferroptosis not only in skin cancers but also potentially in a variety of diverse skin
disorders as well.
2.4 Supplemental Information

Fig. S1. (A) qRT-PCR of Mll4-SET expression in isolated bulk epidermis of 3-week-old Mll4-eKO and control mice
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of 3-week-old Mll4-eKO and control mice tongue (n=3 mice per genotype). (E) H&E histological
staining of 3-week-old Mll4-eKO and control mice esophagus (n=3 mice per genotype). (F) IF
staining of 3-week-old Mll4-eKO and control mice epidermis for Keratin-14 (red), CD3 (green),
and DAPI (blue) (n=2 mice per genotype). (G) Quantification of total CD3 positive cells per
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proliferation-selective, or shared sites in differentiated (red, n=3) or proliferating (blue, n=2)
keratinocytes by average profiles (B) or heatmap (C). (D) Top known (left) or de novo (right)
motifs enriched at MLL4 binding sites at differentiation-, proliferation-selective, or shared sites.

Fig. S3. A) qRT-PCR of Mll3-SET expression in isolated bulk epidermis of 3-week-old Mll3-eKO and control mice (n=34 mice per genotype. p<0.01). (B) Representative 1–year-old Mll3-eKO and control mice. (C) Venn diagrams showing
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eKO upregulated (left) or downregulated (right) genes. (D) IF staining of Krt14-Cre(+); Mll4fl/fl;
Mll3+/fl and control mice epidermis for Keratin-14 (red), and DAPI (blue) (n=3 mice per
genotype). (E) Representative adult Krt14-Cre(+); Mll4fl/+ ; Mll3fl/fl and control mice. (F, H) H&E
histological staining of Krt14- Cre(+); Mll4fl/+ ; Mll3fl/fl and control epidermis (n=3 mice per
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genotype). (G) IF staining of Krt14-Cre(+); Mll4fl/+ ; Mll3fl/fl and control mice epidermis for
Keratin-14 (red), Keratin-10 (green), and DAPI (blue) (n=3 mice per genotype). (H) Expected and
observed percentiles for the offspring resultant from crosses between Krt14-Cre(+); Mll4fl/+ ;
Mll3fl/+ and Krt14-Cre(-); Mll4fl/fl; Mll3fl/fl mice (n=35 mice total). Scale bar: 100 µM unless
otherwise noted.

Additional supplementary data files (RNA- and ChIP-sequencing files) are
available at https://science.org/doi/10.1126/sciadv.abj9141.
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2.5 Methods
NHEK isolation and culture
Primary epidermal progenitors were isolated from deidentified discarded neonatal
human foreskin obtained by Core B of the Penn Skin Biology and Diseases and
Resource-based Center. Primary human keratinocyte cultures used for organotypic
epidermis were isolated from human foreskin procured by the Penn Skin Biology and
Disease Resource-based Center under a protocol (#808224) approved by the University
of Pennsylvania Institutional Review Board and determined to be exempt for formal
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informed consent for use of discarded, deidentified tissues. Foreskin was incubated at
4°C for 12 hours in dispase II (2.4 U/ml). Sterile forceps were used to separate the
underlying dermis. The epidermal sheet was transferred to a 60-mm tissue culture plate,
incubated in 0.25% trypsin for 10 min at 37°C, and then neutralized with 1 ml of fetal
bovine serum (FBS). Sterile forceps were used to scrape the epidermal sheet against
the dish to dissociate cells. The suspension was passed through a 40- µm strainer and
then centrifuged at 200g for 5 min. The cell pellet was resuspended in 5 ml of
keratinocyte medium. Epidermal progenitors were cultured in a 50:50 mix of 1x
keratinocyte serum-free medium (SFM) supplemented with human recombinant
epidermal growth factor (EGF) and bovine pituitary extract combined with medium 154
supplemented with human keratinocyte growth supplement and 1% penicillinstreptomycin (10,000 U/ml) at 37°C.
Murine models and phenotypic analysis
All animal protocols were reviewed and approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania. Mice were maintained on a mixed
C57BL/6 background on a standard light-dark cycle. Mice carrying Mll4SET floxed
alleles, Mll3SET floxed alleles, or a combination of both were crossed with Krt14-Cre
transgenic mice. Krt14-Cre: Mll4SETfl/fl (Mll4-eKO), Krt14-Cre: Mll3SETfl/fl (Mll3-eKO),
triple floxed combinations (Krt14-Cre: Mll4SETfl/fl Mll3SET+/fl or Krt14-Cre: Mll4SET+/fl
Mll3SETfl/fl), and the quadruple flox combination (Krt14-Cre: Mll4SETfl/fl Mll3SETfl/fl)
were considered mutants. Unless noted otherwise, littermates homozygous for the Mll
alleles of interest lacking Krt14-Cre were used as controls. A similar approach was used
using Krt14-CreERtam (005107, Jackson Laboratory) transgenic mice. To activate
inducible knockouts, tamoxifen (T5648-1G, Sigma-Aldrich) was resuspended in corn oil
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(C8267, Sigma-Aldrich) and used for injections. Both genotype controls and corn oil
(vehicle) controls were used to account for the potential effects of tamoxifen. Generation
of Mll4SETfl/fl and Mll3SETfl/fl mice has been described elsewhere [119, 133]. For
genotyping, polymerase chain reaction (PCR) was done using a Thermo Phire Animal
Tissue PCR kit (F140WH) using the following primers: Mll3 (forward:
GTCATCGGTGTGGTCTG AATGA and reverse: AACCGGAAGGAGAAGCTTTATGA),
Mll4 (forward: CAGT TGAGCTAGTCAAGTGATT and reverse:
TTCAATGTGGAGGGGAGTGACAG), and Cre (forward: GAACCTGATGGACATGG and
reverse: AGTGCGTTCGAAC GCTAGAGCCTGT). Unless otherwise stated, all
experimental mice were a mix of male and female. The number of animals used per
experiment is stated in the figure legends.
Following euthanasia, mice at 21 days of age were measured for total body
weight. Data figures are the composite of multiple litters of Mll4-eKO or littermate
controls. A one-way analysis of variance (ANOVA), followed by Tukey’s multiple
comparisons test was used to calculate significant differences between groups for all
mice when stratified by gender and genotype (Fig. 1B). A Student’s t test was used to
calculate significance between groups when considered for genotype only (fig S1C). All
P are noted in figure legends and were considered significant if P < 0.05 and
nonsignificant (NS) if P > 0.05.
Murine RNA and protein extraction
Murine epidermis was dissociated from the dermis before isolation of bulk RNA
and protein. Time points were selected as to not include the anagen phase of the hair
cycle, which compromises the dissociation process. Following euthanasia of 21-day-old
mice, the skin was dissected, and the underlying fat pad was removed using a scalpel.
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The resulting tissue was floated dermis side down in dispase (5 U/ml; Corning) in PBS
for 40 min at 37°C. The epidermis was then removed using a scalpel, and for RNA, the
epidermis was flash-frozen in TRIzol and stored at −80°C until RNA isolation. RNA was
extracted using a RNeasy kit (#74104, QIAGEN) at the same time and date for all mice
belonging to a single experimental cohort (i.e., RNA-seq) regardless of the date of
murine euthanasia to reduce batch effects and stored at −80°C. For protein, epidermis
was placed directly into cold PBS and centrifuged at 4°C for 5 min at 2500 rpm. To the
resulting pellet, protein lysis buffer (Cell Signaling Technology) containing a protease
inhibitor cocktail was added, and the mixture was homogenized, sonicated, rotated at
4°C for 10 min, and then centrifuged at 4°C at full speed for 10 min. Lysates were
quantified using the Bradford assay. Frozen lysates were stored at −80°C.
Real-time PCR
Complementary DNA was obtained using a high-capacity RNA-to-DNA kit
(#4368814, Thermo Fisher Scientific). For quantitative real-time PCR, Power SYBR
Green PCR Master Mix (#4367659, Thermo Fisher Scientific) was used. Primer
sequences are available on request. Quantitative real-time PCR data analysis was
performed by first obtaining the normalized cycle threshold (CT) values (normalized to
glyceraldehyde-3 phosphate dehydrogenase and 18S ribosomal RNA), and the 2 − ∆∆Ct
method was applied to calculate the relative gene expression. ViiA 7 Real-Time PCR
System was used to perform the reaction (Applied Biosystems). The average and SDs
were assessed for significance using a Student’s t test. All P are noted in the figure
legends and were considered significant if P < 0.05 and nonsignificant (NS) if P > 0.05.
RNA sequencing
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RNA-seq libraries were prepared at the same time for all samples belonging to a
single experimental cohort to reduce batch effects. All RNA-seq libraries were prepared
using the NEBNext Poly(A) mRNA magnetic isolation module, followed by NEBNext
Ultra Directional RNA library preparation kit for Illumina. Library quality was checked by
Agilent BioAnalyzer 2100, and libraries were quantified using the Library Quant Kit for
Illumina. Libraries were then sequenced using a NextSeq500 platform [75–base pair (bp)
single end reads]. All RNA-seq was aligned using RNA STAR [150] under default
settings to Mus musculus GRCm38 fragments per kilobase per million mapped
fragments, and generation and differential expression analysis were performed using
DESeq2 [151]. Statistical significance was obtained using an adjusted P value (Padj)
generated by DESeq2 of less than 0.05.
ChIP sequencing
ChIP-seq was performed as described previously [59]. Briefly, keratinocytes
cultured in 10-cm2 dishes were fixed in 1% formaldehyde for 5 min, and fixation was
quenched with the addition of glycine to 125 mM for an additional 5 min. Cells were
harvested by scraping from plates and washed twice in 1x PBS before storage at −80°C.
ChIP extracts were sonicated for 15 min in a Covaris sonicator. All ChIPs were
performed using 500 µg of extract and 2 µg of antibody per sample (anti-MLL4). Thirty
microliters of Protein G Dynabeads was used per ChIP. ChIP DNA was also used to
make sequencing libraries using a NEBNext Ultra DNA library preparation kit for
Illumina. Library quality was checked by Agilent BioAnalyzer 2100, and libraries were
quantified using the Library Quant Kit for Illumina. Libraries were then sequenced using
a NextSeq500 33 platform (75-bp, single-end reads). After sequencing, all data were
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demultiplexed from the raw reads using Illumina’s BCL2FASTQ from BaseSpace.
Further ChIP-seq analysis is described below.
ChIP-seq data processing
ChIP-seq data were analyzed as previously described [152]. Briefly, FASTQ
reads from lanes 1 to 4 were combined for each sample and aligned to Homo sapiens
genome (hg19 UCSC) using bowtie2 (version 2.1) [153], allowing one mismatch per
seed (-N 1) and reporting one alignment per read (-k 1). Alignment files were filtered with
SAMtools (version 1.1) [154] to remove unmapped reads (-F 4) and reads with a
mapping quality inferior to 10 (-q 10). After sorting and indexing, alignment files were
further filtered to remove reads mapped to mitochondrial chromosome or unplaced
contigs (chrM, chrUn, and chrN_random). MLL4 (KMT2D) peaks were called with
HOMER (version 4.6) [155]. Tag directories were generated for each replicate using an
estimated fragment length of 150 bp, allowing one tag per base pair (makeTagDirectory
-fragLength 150 -tbp 1). Tag directories from replicates were combined with HOMER
makeTagDirectory using an estimated fragment length of 150 bp (-fragLength 150).
MLL4 peaks were called for each condition (proliferating or differentiated NHEK) from
merged tag directories using their corresponding input with HOMER findPeaks (-style
factor -size 200 -fragLength auto -F 2 -fdr 0.005), yielding 967 MLL4 peaks in
proliferating NHEKs and 2954 MLL4 peaks in differentiated NHEKs. MLL4 peaks from
both conditions were combined, sorted, merged, and filtered to remove peaks with less
than 1 read per million, yielding 3468 peaks, and condition-selective MLL4 peaks were
defined by a fold-change threshold of 2, yielding 1870 common peaks, 209 proliferationselective MLL4 peaks, and 1369 differentiation-selective MLL4 peaks. Analysis of
transcription factor–binding motifs at each peak set was performed using HOMER
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findMotifsGenome.pl script with default parameters, scaling sequence logos by
information content (−bits).
GO analyses
All GO analyses were performed using PANTHER at http://pantherdb. org/ to
determine statistically overrepresented GO terms using Fisher’s exact test under the
category “biological process.” P values for GO terms are false discovery rate statistics.
The top eight plotted GO terms represent the GO terms with the highest fold enrichment
under PANTHER’s default hierarchical clustering categorization. GO term figures are
generated using ggplot2.
Co-immunoprecipitation experiments
Co-immunoprecipitation (Co-IP) experiments were performed as previously
described [156] .Briefly, 30 ml of magnetic Protein G Dynabeads were washed twice in 1
ml of 0.5% bovine serum albumin (BSA), resuspended in 250 ml of 0.5% BSA, and
conjugated for 1 to 2 hours at 4 C under rotation with 1 mg of antibodies against either
MLL4 or immunoglobulin G (IgG) as a negative control. About 500,000 proliferating
epidermal progenitors cells were harvested from a 10-cm culture plate at 50%
confluence and lysed for 1 hour at 4 C under rotation in 250 ml of IP buffer [20 mM tris
(pH 7.5), 134 mM NaCl, 1 mM CaCl2, 1% NP-40, and 10% glycerol] supplemented with
freshly made 1 mM MgCl2, 1:100 Halt protease and phosphatase inhibitor cocktail
(catalog no. 78440, Thermo Fisher Scientific), and benzonase at 12.5 U/ml. Benzonase
is critical for the efficient release of chromatin-bound proteins to the supernatant, and
MgCl2 is critical for its activity. Cell lysates were centrifuged at top speed for 10 min. Cell
lysate (500 mg) was incubated overnight at 4 C with antibody conjugated magnetic
beads previously washed three times with 1 ml of 0.5% BSA. Immunoprecipitates were
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collected using a magnet; washed four to five times with IP buffer devoid of MgCl2,
protease/phosphatase inhibitors, and benzonase; then boiled with NuPage loading dye,
and analyzed by Western blotting. Antibodies used during Co-IP and subsequent
immunoblotting include anti-MLL4 (Sigma-Aldrich, HPA035977-100UL), anti-P53 (EMDMillipore, MABE327), and IgG (Santa Cruz, sc-2005).
Immunoblotting
Samples were separated by electrophoresis in 4 to 20% SDS–polyacrylamide gel
electrophoresis gels with 20 mg per lane, transferred to a polyvinylidene difluoride
membrane, and blotted with antibodies. Secondary horseradish peroxidase–conjugated
secondary antibodies (Santa Cruz Biotechnology) and Amersham ECL Prime Western
Blotting Detection Reagents (catalog no. RPN2232, GE Healthcare) were used for
detection. Antibodies used during immunoblotting include anti-actin (Santa Cruz, sc1616), anti-RARg (Santa Cruz, sc-7387), and anti-Alox12 (Santa Cruz, sc-365194).
Histology
Mouse dorsal and ventral skin tissues were processed for histological
examination by Core A of the Penn Skin Biology and Disease Resource-based Center
and mounted on frost-free slides. H&E staining was processed by Penn Skin Biology
and Disease Resource-based Center Core A. A Leica DM6 B microscope was used to
observe and capture representative images. Exposure times and microscope intensity
were kept constants for all human samples and across mouse littermate comparisons.
Immuno-histochemistry and -fluorescence
IHC: Tissue slides were baked for 1 hour at 65°C, deparaffinized in xylene, and
rehydrated through a series of graded alcohols. After diH2O washes, slides were treated
with antigen unmasking solution (1:100; SKU H-3300-250, Vector Laboratories) at 95°C
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for 10 min according to the manufacturer’s protocol. Blocking and primary antibody
binding were detected using a VECTASTAIN Elite ABC-HRP system according to the
manufacturer’s instructions (catalog no. PK-6200, Vector Laboratories). After O/N
primary antibody (see antibody table) incubation at 4°C, endogenous peroxidases were
blocked with 3% hydrogen peroxide in MeOH for 10 min at room temperature (RT),
treated with biotinylated secondary anti-mouse/rabbit antibody at RT for 90 min, and
treated with ABC reagent (VECTASTAIN Elite ABC-HRP Kit, PK-6200, Vector
Laboratories) for 30 min at RT. The staining was visualized with 3,3′-diaminobenzidine
(catalog no. SK-4100, Vector Laboratories) as peroxidase substrate. Exposure times
were synchronized so that all tissues samples within an antibody group were exposed to
3, 3’-diaminobenzidine (DAB) for the exact same time. All slides were counterstained
with hematoxylin (Hematoxylin QS, H-3404, Vector Laboratories) for 35 s at RT,
dehydrated in ethanol, cleared in xylene, and mounted with VectaMount (permanent
mounting medium, H-5000, Vector Laboratories). Antibodies used for IHC include anti4HNE (abcam, ab46545), anti-SCNN1a (Proteintech, 10924-2-AP), and anti-ALOX12
(Santa Cruz, sc-365194).
IF: Mouse tissues slides were deparaffinized with xylene, rehydrated with
alcohol, and treated with Targeting Unmasking Fluid (1:3; catalog no. Z000R.0000, Pan
Path) at 90°C for 10 min according to the manufacturer’s protocol. Slides were
permeabilized with 0.5% Triton X-100 in Dulbecco’s PBS for 10 min and incubated in
BlockAid Blocking Solution (Thermo Fisher Scientific, catalog no. B10710) for 1 hour at
RT in a humidity chamber and incubated O/N in primary antibody. Following secondary
antibody treatment (see antibody table) for 30 min at RT, the sections were mounted
with ProLong Gold with 4′,6-diamidino-2-phenylindole (DAPI) (catalog no. P36935,
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Thermo Fisher Scientific). Antibodies used for IF include anti-KRT14 (abcam, ab7800),
anti-KRT10 (abcam, ab7638), anti-H3K4me1 (abcam, ab8895), anti-RARg (Santa Cruz,
sc-7387), and anti-CD3 (Biolegend, 300324).
3D human skin organoids
The 3D human skin organoids were performed as previously described [144].
Briefly, J2 3T3 fibroblasts were grown in Dulbecco’s modified Eagle’s medium (DMEM) +
10% FBS. Cells were released from culture plates using 0.25% trypsin for 5 min at 37 C,
resuspended in DMEM + 10% FBS, and counted using a hemocytometer to determine
the volume needed to obtain 0.75 million to 1 million fibroblasts per organotypic culture.
The required volume was centrifuged in a 50-ml sterile conical tube at 200g for 5 min,
and the supernatant was removed. The fibroblast cell pellet was resuspended in 1/10 the
final required volume (2 ml per culture) of 10x collagen resuspension buffer (1.1 g of
NaHCO3 plus 2.39 g of Hepes in 50 ml of 0.05 N NaOH) and held on ice. One-tenth the
final volume of 10x DMEM (Sigma-Aldrich) was then added, and the cells were mixed by
vigorous pipetting. Purified high-concentration rat tail collagen I (Corning) was added
and diluted with sterile diH2O to a final concentration of 4 mg/ml of the final volume.
NaOH (0.05 N) was added to a pH of approximately 7. The collagen-fibroblast slurry was
mixed by inverting, and then, 2 ml was pipetted into the top chamber of a six-well
transwell insert (Corning) placed within a deep-well six-well tissue culture plate
(Corning). The fibroblast-collagen matrices were allowed to polymerize at 37°C for 60
min. Then, the matrices were submerged in DMEM + 10% FBS and placed at 37°C O/N.
The next day, NHEKs were trypsinized, resuspended in DMEM + 10% FBS, counted to
collect 1 million cells/culture, and centrifuged at 200g for 5 min. The NHEK pellet was
resuspended in E-medium supplemented with EGF (5 ng/ml; Sigma-Aldrich) to a volume
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of 2 ml/culture. The DMEM was removed from both the top and bottom chambers of the
transwell plates containing the collagen-fibroblast matrices. A total of 2 ml of NHEKs (1
million cells) were seeded atop each matrix in the top transwell chamber, and 14 ml of Emedium with EGF (5 ng/ml) was added to the bottom chamber. The cultures were
placed at 37°C overnight. The next day, the medium was aspirated from both the top
and bottom chambers of the transwell. To place the NHEK monolayers at an air-liquid
interface and induce stratification, 10 ml of E-medium (without EGF supplementation)
was added only to the bottom chamber of the transwell, and the cultures were grown at
37°C for up to 12 days, feeding 10 ml of E-medium every other day. DFP (#379409,
Sigma-Aldrich) was used at 1 mM, and cultures were treated on day 6 at the air-liquid
interface with either DFP or dimethyl sulfoxide (DMSO) vehicle, then allowed to grow for
72 more hours, and fixed in formalin for routine histology (N = 5 unique NHEK isolates
were used and showed similar effects).
Publicly available data
TCGA analysis: RNA-seq datasets from head and neck SCC and bladder cancer
were obtained from TCGA (https://tcga-data.nci.nih.gov/tcga). Original RNA expression
values (normalized read counts) were used for downstream analyses. For each cancer
type, samples were ranked by MLL4 expression levels and were evenly divided into four
groups. Comparisons were performed between the group of samples with the highest
MLL4 expression and the group of samples with lowest MLL4 expression. One-sided
Wilcoxon rank-sum tests were used to compute significance. Human protein atlas IHC
data derived from the Human Protein Atlas can be found at www.proteinatlas.org/
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Statistical analyses
All statistical analyses were performed using R or GraphPad Prism Details of
each statistical test are included in above Materials and Methods. Sample sizes and P
values are included in the figure legends or main figures. Investigators were not blinded
during experiments or outcome assessment.
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Chapter 3: LSD1 inhibition promotes epithelial differentiation through
derepression of fate-determining transcription factors
This chapter includes work adapted from a previously published manuscript in Cell
Reports [157] .
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3.1 Introduction
Mutations in chromatin modifiers occur in approximately 50% of all human
cancers and are often associated with poor disease prognosis [15]. By altering
chromatin structure, these mutations can give rise to each of the classic hallmarks of
cancer [158]. Inhibitors of epigenetic enzymes can overcome tumor differentiation blocks
through epigenetic reprogramming [159, 160].
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Epigenetics plays a particularly crucial role in self-renewing somatic epithelia,
where stem cell populations must continually undergo self-renewal [12]. Understanding
the specific transcription factors and epigenetic modifying enzymes necessary for proper
regulation of the highly orchestrated transcriptional networks in normal epidermis, and
how they are disrupted in epidermal cancers, may provide a unique opportunity for
epigenetic therapeutic intervention.
The chromatin modifier LSD1 (KDM1A) is a histone lysine demethylase critical
for organismal development and differentiation and is frequently overexpressed in
human cancers [69, 93, 94, 102, 103, 161]. LSD1 acts primarily as a gene silencer by
removing histone H3 lysine 4 (H3K4) mono-methylation and di-methylation (H3K4me1/2)
[72, 78]. LSD1 is involved in repression of developmental programs and maintenance of
pluripotency [72], as well as stem cell self-renewal and cellular differentiation in
myocytes, adipocytes, and during hematopoiesis [162-164]. Despite this, the
fundamental biological roles of LSD1 in the skin are virtually unknown. Here we show
that pharmacologic LSD1 inhibition promotes a genome-wide loss of LSD1 binding and
broad increases in H3K4 methylation and transcription at canonical epidermal
differentiation-promoting transcription factors (TFs) and inhibits Ras-driven invasive
neoplasia. Together, these results highlight the potential therapeutic utility of targeting
epigenetic reprogramming for keratinocyte cancers (i.e., cutaneous squamous cell
carcinoma [cSCC] and basal cell carcinoma [BCC]), which collectively outnumber all
other human malignancies combined [33].
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3.2 Results
3.2.1 LSD1 Inhibition unleashes the epidermal differentiation transcriptional program
LSD1 levels are elevated in epithelial cancers such as squamous cell carcinoma,
while the opposing H3K4 histone methyltransferases, KMT2C (MLL3) and KMT2D
(MLL4), display exceptionally high rates of loss-of-function mutations [118, 165-167].
Together, this provides extensive rationale to understand how LSD1 functions in
epithelial tissues given its potential to be inhibited with specific drugs [168, 169]. To
address this, we pharmacologically inhibited LSD1 in EPs using an irreversible, catalytic
inhibitor of LSD1, GSK-LSD1. Consistent with the known function of LSD1 as a
transcriptional repressor, after 48 h of exposure to 2 mM GSK-LSD1 or DMSO, RNA-seq
differential gene expression analysis identified many more genes as upregulated (863)
than downregulated (350) (Fig. 5A, B). We observed a similar trend using a second
LSD1 inhibitor, tranylcypromine (2-PCPA) (Fig. 5C and fig. S4A). Strikingly, treatment
with either of these two distinct LSD1 inhibitors led to highly overlapping sets of
transcriptional alterations genome-wide (Fig. 5D and fig S4D) from all expressed genes.
Gene ontology (GO) analysis of the genes upregulated by GSK-LSD1 (Fig. 5E), 2-PCPA
(fig. S4B), or the genes overlapping between each drug highlighted genes involved in
skin barrier homeostasis, keratinocyte differentiation, and cornification (fig S4C). Genes
downregulated were enriched for genes involved in extracellular structure organization,
cell adhesion, and biological adhesion (fig S4E). Numerous TFs known to be critical for
epidermal progenitor differentiation were among the most highly expressed genes upon
LSD1 inhibitor treatment, including OVOL2, GRHL1, NOTCH3, MAML3, MAFB, and
KLF4 (Fig. 5F) [170-175]. Interestingly, GLI1, the most highly downregulated
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transcription factor in GSK-LSD1-treated EPs (Fig. 5G), is a known driver of BCC and
other cancers [176].
We next asked whether the LSD1-inhibited epidermal progenitor transcriptome
overlapped with EPs differentiated in vitro [177]. We compared the gene expression
profile of differentiated EPs (fig. S4F) with that of LSD1 inhibitor-treated EPs and found a
significant intersection for both upregulated (Fig. 5H) and downregulated genes (fig.
S4G), including key upregulated (Fig. 5I, L) or downregulated (fig S4H, I) established
epidermal differentiation TFs. Intersection between the TFs upregulated by LSD1
inhibition and TFs deemed as critical for epidermal pro-genitor differentiation [178]
yielded a restricted number of TFs including all three members of the Grainyhead-like
family of TFs (GRHL1, GRHL2, and GRHL3), together with OVOL2, NOTCH3, and KLF4
(fig S4J, K). Consistent with our initial results, exposure to 6 days of GSK-LSD1 at the
same dose (2 mM) led to similar, but even more pro-found transcriptional changes than
those at 48 h or 2 days, including more upregulated genes (1,678) than downregulated
genes (1,377) (fig S5A). Analysis of genes commonly upregulated or downregulated by
2 or 6 days of GSK-LSD1 revealed highly significant overlap between the two RNA-seq
datasets (fig. S5B, C), with upregulated genes enriched for genes involved in epidermal
differentiation, cornification, and keratinization (fig. S5G), whereas genes commonly
downregulated were enriched for genes contributing to extracellular matrix organization,
collagen fibril organization, and heterotypic cell-cell adhesion (fig. S5H). In addition,
there was an even more significant overlap between 6-day GSK-LSD1-treated EPs and
invitro-differentiated EPs than those treated for 2 days with GSK-LSD1, both at the gene
(Fig. 5J and fig. S5D) and transcription factor (Fig 5K, and fig S5E, F) level. These
changes include numerous TFs known as key determinants of epidermal progenitor
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differentiation, such as NOTCH3, OVOL1, ZNF750, GRHL1, and GRHL3 (Fig. 5M). We
next investigated the expression of the 288 genes that define the GO term ‘‘keratinocyte
differentiation’’ (GO:003216) and found that although 2-day exposure to GSK-LSD1
resulted in a moderate increase in expression of epidermal progenitor differentiation
genes, 6-day exposure to GSK-LSD1 triggered a dramatic increase in their expression
and included numerous established differentiation genes (i.e., DSG1, SPRR1B, PI3,
KLK13, KRT1, and CDSN) (Fig. 5N).
Finally, we treated EPs with siRNAs against LSD1 to determine whether genetic
knockdown recapitulated our results with the pharmacological LSD1 inhibitors. After 72 h
of siRNA treatment, LSD1 protein abundance was significantly reduced (fig S5I). RNA
sequencing (RNA-seq) demonstrated that although the changes in the transcriptional
landscape were not as broad as the inhibitors, genes significantly upregulated by siLSD1
treatment were again enriched for genes involved in epidermal cornification and
keratinocyte differentiation (fig, S5J, K). The majority of upregulated genes overlapped
with genes upregulated by GSK-LSD1 treatment (fig. S5L) and those overlapping genes
were enriched for epidermal cornification and differentiation (fig. S5M). Even though
GRHL1 and GRHL3 were again upregulated, it did not quite reach statistical
significance, although several known targets of these epidermal differentiation TFs were
significantly increased in gene expression, such as KRT80, IVL, and DSG1 (fig. S5N).
Together, these data link LSD1 to the transcriptional repression of differentiation genes
and TFs in EPs. Furthermore, these differentiation gene expression programs can be
unleashed with inhibition of LSD1.
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Fig. 5. LSD1 Inhibitor Treatment of Epidermal Progenitors Unleashes a Pro-differentiation
Transcriptional Program. (A–C) Differentially expressed genes after 2 day of LSD1 inhibition by
GSK-LSD1 (A and B) and 2-PCPA (C). (D) Overlap between genes upregulated by 2-day GSKLSD1 (863 genes) and 2-PCPA (1,161 genes). (E) GO analysis of genes upregulated by GSKLSD1 (F and G) Log2 fold change values of the 50 most upregulated (F) and 37 most
downregulated (G) transcription factor-encoding genes after 2-day GSK-LSD1. (H) Overlap
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between genes significantly upregulated by 2-day GSK-LSD1 and during in vitro epidermal
differentiation. (I) Overlap between transcription factor-encoding genes significantly upregulated
by 2-day GSK-LSD1 and during in vitro epidermal differentiation. (J) Overlap of genes
significantly upregulated by 6-day GSK-LSD1 and during in vitro epidermal differentiation (K)
Overlap between transcription factor-encoding genes significantly upregulated by 6-day GSKLSD1 and during in vitro epidermal differentiation. (L) transcription factor-encoding genes
upregulated by 2-day GSK-LSD1 and in vitro epidermal differentiation, sorted by decreasing log2
fold change. (M) The 25 most differentially regulated transcription factor-encoding genes
commonly upregulated by 6-day GSK-LSD1 and in vitro epidermal differentiation, sorted by
decreasing log2 fold change (N) Genes that define the gene ontology term ‘‘keratinocyte
differentiation’’ (GO:0030216) upon in vitro epidermal progenitor differentiation, after 2- or 6-day
GSK-LSD1.

3.2.2 LSD1 inhibition prevents LSD1 binding at SNAI2-repressed epidermal
differentiation genes
Having found LSD1 inhibitors induce a differentiation-related transcriptional
program in EPs, we hypothesized that LSD1 may be enriched at the regulatory elements
of key epidermal progenitor differentiation genes. To test this, we mapped LSD1 binding
genome-wide using chromatin immunoprecipitation followed by sequencing [ChIP-seq])
in EPs treated with DMSO or GSK-LSD1 (2 mM). Irreversible LSD1 inhibitors, such as
GSK-LSD1, have been reported to prevent binding of LSD1 to the genome in addition to
inhibiting LSD1’s catalytic activity [113]. Consistent with this, GSK-LSD1 treatment
dramatically reduced LSD1 binding to chromatin genome-wide. Differential binding
analysis identified 1,432 lost LSD1 binding sites with GSK-LSD1, whereas 1,174 LSD1
sites were maintained, and only 14 sites demonstrated increased binding (Fig. 6A-E).
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Lost LSD1 peaks were enriched at promoters, defined here as sequences located up to
1 kb upstream of a gene’s transcriptional start site, thus also encompassing local
enhancer regions. Together, this suggests that LSD1 is preferentially lost from regulatory
elements upon LSD1 inhibition (Fig. 6F). In line with this, analysis of the genes nearest
to each GSK-LSD1 lost LSD1 peak showed that the majority (71%) were associated with
protein-coding genes (fig S6A).
We next integrated these data with our RNA-seq results to identify genes that
had upregulated gene expression and loss of LSD1 binding upon LSD1 inhibition. A total
of 146 genes (Fig. 6H), of which 23 were TFs (Fig. 6I), were both upregulated by LSD1
inhibition and associated with LSD1 lost sites. Importantly, TFs critical for epidermal
progenitor differentiation (i.e., GRHL1, GRHL3, NOTCH3, KLF4) were among the 146
genes (Fig. 6J). This suggests that the majority of the transcriptional effects resulting
from LSD1 inhibition are driven secondarily through LSD1’s direct role in regulating
expression of key TFs. There was no significant overlap between LSD1 binding sites
that were maintained, and genes upregulated (fig S6B) or downregulated (fig. S6C) by
GSKLSD1. GO analysis of the 146 overlapping genes again demonstrated a strong
enrichment of terms involved in epidermal differentiation and cornification (fig S6D),
whereas those shared sites between DMSO- and GSK-LSD1-treated EPs did not (fig.
S6E).
We then evaluated transcription factor binding motifs that were enriched at LSD1
binding sites lost upon GSK-LSD1 treatment. This identified Fra1 (FOSL1) and SNAI2
(Slug) as the top two most highly enriched motifs at these sites (Fig. 6G), both known
critical regulators of keratinocyte differentiation [178-180]. SNAI2, acting through its
SNAG domain, has been reported to recruit LSD1 to target genes in mammary, colon,
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and neuroblastoma cancer cells in vitro [96]. Because the primary function of SNAI2 in
epidermal progenitors is transcriptional repression of keratinocyte differentiation [180],
we next performed coimmunoprecipitation (coIP) experiments using full-length
endogenous LSD1 and SNAI2 proteins from human EPs and found that LSD1 and
SNAI2 indeed do directly interact in this context (Fig. 6M and fig S6L). Furthermore,
transcriptional changes induced by LSD1 inhibition significantly overlap with those seen
with SNAI2 inhibition (fig. S6G–S6J), including the upregulation of genes involved in
epidermal differentiation and cornification (fig. S6K). Collectively, these observations
suggest that inhibiting LSD1 in EPs may block LSD1/SNAI2 binding and induce
differentiation via activation of SNAI2-repressed target genes.
This prompted us to query publicly available SNAI2 ChIP-seq data from EPs
[180]. Consistent with our motif analysis, overlap between SNAI2 peaks and GSK-LSD1
lost sites indicates that GSK-LSD1 lost sites are significantly associated with SNAI2
binding sites (Fig. 6K). These included genes involved in epidermal differentiation, such
as HES5, CLDN1, CLDN7, and PPL (Fig. 2N, O and fig S6M, N) [181, 182]. In contrast,
shared DMSO-and GSK-LSD1-treated LSD1 peak regions did not overlap significantly
with SNAI2 peaks (Fig. 6L), nor did these genes increase in expression (Fig 6P, Q).
Furthermore, transcription factor binding motifs associated with LSD1 sites shared
between DMSO- and GSK-LSD1-treated samples included different transcription factor
binding motifs, e.g., Nkx2–5, Vdr, and Smad3–1 (fig. S6F). Together these data indicate
that GSK-LSD1 both inhibits LSD1 catalytic activity and blocks a significant proportion of
LSD1 binding to its targets, and that these LSD1 lost sites overlap with SNAI2
transcription factor binding sites. We also demonstrate that LSD1 and SNAI2 directly
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interact, collectively suggesting that LSD1 is required for SNAI2-mediated transcriptional
repression, and that LSD1 inhibitors may block this repressive function.

Fig. 6. LSD1 Inhibition Prevents LSD1 Binding to Epidermal Differentiation Genes and
SNAI2 Binding Sites. (A) ChIP-seq demonstrates dramatic reduction in LSD1 peaks with LSD1
inhibition. (B) Comparison of FPKM normalized LSD1 binding intensities in DMSO- or GSK-
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LSD1-treated EPs. (C and D) LSD1 binding intensities at shared, GSK-LSD1 lost, or GSK-LSD1gained LSD1 sites (1 kb apart peak center) by heatmap (C) and violin plot (D). (E) Average
profiles of LSD1 binding at shared, GSK-LSD1 lost, and GSK-LSD1-gained sites. Solid lines
represent LSD1 binding with DMSO, whereas dotted lines represent LSD1 binding with GSKLSD1. (F) Distribution of LSD1 binding sites at shared, GSK-LSD1 lost, and GSK-gained LSD1
sites (numbers = log2 enrichment). (G) Top de novo motifs associated with GSK-LSD1 lost sites.
(H and I) Overlap between genes (H) and transcription factor-encoding genes (I) upregulated by
GSK-LSD1 and associated with GSK-LSD1 lost LSD1 sites. (J) Log2 fold changes (left) and
LSD1 binding intensities (right) for GSK-LSD1 upregulated TFs with GSK-LSD1 lost LSD1 sites.
(K) Overlap of GSK-LSD1 lost LSD1 sites and SNAI2 binding sites (GSE55421- [180]). (L)
Overlap of LSD1 peaks common to DMSO- and GSK-LSD1-treated samples and SNAI2
peaks.n(M) LSD1 IP pulls down SNAI2 by coIP.n(N and O) LSD1 and SNAI2 shared target genes
that lose LSD1 binding and increase in expression, HES5 (N) and CLDN1 (O). (P and Q) LSD1
bound genes that do not lose LSD1 binding or increase in expression, HIST1H4C (P) and
ZNF687 (Q), highlighting absence of SNAI2 binding.

3.2.3 LSD1 inhibition increases H3K4 methylation at epidermal differentiation genes and
transcription factors
Because loss of LSD1 binding at SNAI2-repressed epidermal progenitor
differentiation genes correlated with an upregulation of these genes, we hypothesized
that LSD1 inhibitors may enrich the regulatory elements of these genes with H3K4
methylation, leading to their activation. To test this, we mapped H3K4me1 and
H3K4me2 genome-wide in DMSO- or GSK-LSD1-treated EPs and observed a global
increase of 15% in H3K4 monomethylated regions and approximately 6% in H3K4 dimethylated regions (Fig. 7A). GSK-LSD1 appeared to have a more drastic effect on
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differential H3K4me2 (974 regions) than H3K4me1 enrichment (138 regions) (Fig. 7B, D,
F). Similar to the LSD1 binding sites, the increases in H3K4me1 and H3K4me2 were
enriched at promoter regions in GSK-LSD1-treated samples (Fig. 7C). Consistent with
the known roles of H3K4me1 at enhancers and H3K4me2 at promoters, respectively,
H3K4me2 was more enriched at promoter regions in comparison with H3K4me1 (fig.
S7A).
We next intersected GSK-LSD1 lost LSD1 binding sites with GSK-LSD1-gained
H3K4me1 and H3K4me2 regions and found 24 genes that were associated with lost
LSD1 binding and increases in both H3K4me1 and H3K4me2 (Fig 7E), including OVOL2
and NOTCH3 (Fig. 7H). A total of 151 genes gained only H3K4me2 (Fig. 7E, I), and 17
genes gained only H3K4me1 (Fig. 7E and fig S7C). There were some genes that gained
H3K4me1 and/or H3K4me2 that were not bound by LSD1 in either DMSO- or GSKLSD1-treated EPs, as well as genes that lost LSD1 binding with GSK-LSD1 treatment
but did not demonstrate any significant changes in H3K4 methylation (fig S7D).
Collectively, these data suggest that LSD1 inhibitor treatment had larger effects
on increasing H3K4me2 than H3K4me1 (Fig. 7E). Average profile plots confirmed
specific increases of H3K4 methylation surrounding both total LSD1 lost sites and LSD1
lost sites associated with genes upregulated by GSK-LSD1 (Fig. 7G and fig. S7B). In
contrast, maintained LSD1 sites did not exhibit these increases in H3K4 methylation
(Fig. 7G, center and right compared with left). SNAI2-target genes with lost LSD1
binding, increased H3K4me1 and H3K4me2, and upregulated gene expression following
GSK-LSD1 treatment included the major pro-epithelial differentiation TFs, NOTCH3 and
GRHL3 (Fig. 7H, I).
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Fig. 7. LSD1 Inhibition Drives Genome-wide Increases of H3K4me1 and H3K4me2 in
Epidermal Progenitors. (A) H3K4me1/me2 peaks in DMSO- or GSK-LSD1-treated EPs (n = 2).
(B) GSK-LSD1-gained or lost H3K4me1 and H3K4me2 regions. (C) Distribution of GSK-LSD1gained H3K4me1/me2 regions. Bolded numbers equal log2 enrichment. (D) Average profile plots
of H3K4me1/2 binding at GSK-LSD1-gained H3K4me1/2 regions in DMSO- (blue lines) or GSKLSD1-treated EPs (red lines). (E) Overlap between GSK-LSD1 lost LSD1 sites GSK-LSD1-
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gained H3K4me1 regions and GSK-LSD1-gained H3K4me2 regions (F) H3K4me1/2 binding
occupancy at GSK-LSD1-gained H3K4me1 (left, blue) or H3K4me2 (right, green) regions in
DMSO- or GSK-LSD1- treated EPs. (G) Average profiles of LSD1, H3K4me1/2 binding at LSD1
peaks shared between DMSO- and GSK-LSD1-treated EPs (left panel), at GSK-LSD1 lost LSD1
peaks (center panel) and at GSK-LSD1 lost LSD1 peaks associated with GSK-LSD1 upregulated
genes (right panel). (H and I) ChIP-seq for NOTCH3 (H) and GRHL3 (I), that display overlapping
SNAI2 and LSD1 peaks, lost LSD1 binding with GSK-LSD1, and increases in H3K4me1 and/or
H3K4me2 and concomitant gene expression.

3.2.3 Continued…
Altogether, these results highlight how pharmacological inhibition of LSD1
enzymatic activity in proliferating EPs impaired LSD1 binding at a set of genes
implicated in epidermal progenitor differentiation and triggered their increased
expression along with associated increases in H3K4me1 and H3K4me2. Further-more,
our results suggest that the portion of LSD1 cistrome affected by pharmacological
inhibition of its enzymatic activity might be driven by transcriptional repressors known to
play important roles in inhibiting cell differentiation and maintaining the self-renewal
potential of epidermal progenitors (i.e., FRA1 and SNAI2) [178-180].
3.2.4 LSD1 inhibition promotes epidermal differentiation and represses squamous cell
carcinoma
We next wanted to test how LSD1 inhibition functionally affected epidermal
progenitor differentiation and growth. First, we validated the upregulation of NOTCH3,
GRHL3, KLF4, and AP2-g (TFAP2C) following GSK-LSD1 treatment (Fig. 8A). We then
assessed how proliferating epidermal progenitor cell behavior and fate may be altered
by activation of these pro-differentiation epithelial TFs. GSK-LSD1 treatment significantly
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reduced epidermal progenitor cell growth as compared with DMSO (Fig. 8B). Next, we
used three-dimensional (3D) human organotypic (OTC) skin models to assess the
effects of LSD1 inhibition on epidermal behavior [144]. In contrast with DMSO-treated
controls, which yielded a relatively normal stratified epidermis, GSK-LSD1-treated EPs
showed regions of sporadic cornification, the end product of terminal differentiation
within the epidermis (Fig. 8C), consistent with our data from two-dimensional (2D)
cultures that indicated that LSD1 inhibitors activated epidermal differentiation programs.
We then hypothesized that activating differentiation with LSD1 inhibitors may
inhibit keratinocyte cancers. To test this, we utilized a model of human cSCC in which
proliferating EPs are engineered to express two medically relevant oncodrivers, CDK4
(R24C) and tamoxifen-induced mutant H-RAS (G12V) [183], which are sufficient to
convert normal OTC epidermis into invasive cSCC [184]. Similar to our results in EPs,
GSK-LSD1 treatment of the engineered cSCC-like cells upregulated the expression of
the same pro-epidermal differentiation TFs as compared with DMSO (fig. S7E). In the
invasive cSCC OTC system, DMSO-treated control OTCs produced a thickened
epidermis and invasive projections into the dermis consistent with previous results (Fig.
8D, G) [184]. In contrast, OTCs treated with GSK-LSD1 at 2, 10, or 20 mM exhibited
significantly reduced epidermal area and dermal protrusions, and displayed less invasive
phenotypes (Fig. 8D–8G). Consistent with this, these cultures also showed earlier
flattening and squamatization of the epidermis, as well as expression of differentiation
markers like involucrin (IVL) (fig. S7F).
We next hypothesized that the expression of the pro-differentiation transcriptional
programs upregulated by LSD1 inhibition would be suppressed in human patient cSCCs.
To test this, we queried published gene expression data from human patient cSCCs
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[185]. Indeed, there was significant overlap between those genes suppressed in human
cSCC and those genes upregulated by LSD1 inhibition in EPs after 2 days of GSK-LSD1
(Fig. 8H). Finally, we examined publicly available gene expression data from The Cancer
Genome Atlas (TCGA) for Head and Neck Squamous Cell Carcinoma (HNSCC) given
that HNSCC has been shown to be the most transcriptionally similar cancer to cSCC
[185], and because cSCC gene expression data are currently unavailable in TCGA.
Notably, LSD1 is commonly overexpressed and associated with poor prognosis and
survival in HNSCC [101]. Intriguingly, we found that LSD1 expression was significantly
negatively correlated with the expression of the pro-epithelial differentiation genes
GRHL1, MAML3, NOTCH3, NOTCH1, and CLDN4 in HNSCC (Fig. 8I and fig. S7G), in
accordance with our evidence that LSD1 is a direct repressor of these major prodifferentiation genes and TFs. Together, these data underscore the pro-differentiation
gene expression effects of LSD1 inhibitors in both EPs and cSCC models and highlight
their potential as a pro-differentiation therapy in invasive SCC.
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Fig. 8. LSD1 Inhibition Promotes Differentiation and Represses Squamous Cell Carcinoma.
(A) NOTCH3, GRHL3, KLF4, and AP2-g are upregulated in GSK-LSD1-treated EPs. (B) GSKLSD1-treated EPs display significantly reduced growth compared with DMSO. (C) GSK-LSD1treated 3D human OTCs on collagen rafts prematurely cornify (arrows) as compared with DMSO.
(D) GSK-LSD1-treated oncogenic 3D human OTCs on human dermis prematurely cornify as
compared with DMSO (H&E). (E and F) GSK-LSD1-treated (2, 10, or 20 mM) oncogenic 3D
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human OTCs established on human dermis display significantly less epidermal area (E) and
dermal protrusions (F) than DMSO. Error bars represent SDs. (G) IF of oncogenic 3D OTCs for
Krt14 (red), Collagen VII (green), or DAPI (blue) (original magnification 320; scale bar, 50 mm).
(H) Overlap of genes upregulated by GSK-LSD1 in EPs and genes downregulated in cSCC
compared with normal skin (top). (I) LSD1 expression negatively correlates with expression of
epithelial differentiation TFs in HNSCC data from TCGA.

3.3 Discussion
Self-renewing somatic tissues such as the skin rely on precise epigenetic
changes in order to orchestrate the dramatic transcriptional changes that occur during
the transition from early stem-like EPs into fully differentiated cells [12]. Epigenetic
dysregulation disrupts differentiation and, in turn, can promote disease such as cancer.
Therefore, the ability to potentially reverse disrupted epigenetics through therapies
targeting chromatin regulators is an active area of pharmaceutical research [169].
Given its direct accessibility, the skin is more amenable to use of potentially
broad-based inhibitors of chromatin modifiers given the ability to avoid systemic delivery
and side effects through topical delivery systems. Furthermore, keratinocyte cancers,
made up of BCC and cSCC, outnumber all other human malignancies combined and are
increasing in incidence with the aging of the population [33]. Although generally treatable
with surgery, cSCC in particular displays increased rates of metastasis and death in the
aged and immunocompromised [33]. Interestingly, cSCC has been shown to share
common mutational and transcriptional underpinnings with all other forms of SCC, and
this ‘‘pan-squamous’’ group of cancers displays the highest rates of mutations in
epigenetic modifiers [44, 45, 185]. Together, this underscores the critical importance of
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obtaining an in-depth mechanistic understanding of how these major epigenetic
regulators function in both epithelial homeostasis and disease.
Given that LSD1 is elevated across numerous human cancers and can be
targeted with relatively specific inhibitors [169], we set out to define the role of LSD1 in
the skin. We present evidence that LSD1’s main function within the epidermis is to
actively maintain EPs in their more basal stem cell state through the direct repression of
major TFs driving epithelial differentiation. Inhibition of LSD1 results in a dramatic
reduction of LSD1 binding genome-wide at known SNAI2-repressed canonical epithelial
differentiation genes and TFs [180], and is coupled with broad increases in H3K4
methylation, as well as the expression of these genes. Functionally this results in
reduced proliferation of EPs, as well as reduced growth and invasion in a model of cSCC
[184].
The enrichment of LSD1 binding at SNAI2 target genes, as well as the direct
interaction of LSD1 and SNAI2 in EPs, strongly suggest that LSD1 and SNAI2 might
cooperate to maintain a more stem cell-like state by repressing the epidermal
differentiation program. This finding, together with the well-established function of SNAI2
as a critical regulator of epithelial mesenchymal transition (EMT) in various cancer
contexts [186], suggests that LSD1 inhibition may work through diverse mechanisms
beyond just promoting differentiation to prevent cancer progression. Collectively, these
observations underscore the exciting potential for LSD1 inhibitors to treat cSCC.
Notably, an earlier study of ZNF750, a transcription factor involved in epidermal
differentiation, demonstrated an interaction between LSD1 and ZNF750 [187]. Upon
examining the effects of LSD1 inhibition on a panel of 80 ZNF750-regulated genes, this
study suggested that LSD1 may play a role in the repression of progenitor genes.
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However, our study has employed more comprehensive and unbiased genome-wide and
functional approaches, and through these methods, we are able to show that, on
balance, LSD1’s major role in the epidermis is actually to repress differentiation genes,
because LSD1 inhibition leads to a genome-wide loss of LSD1 binding, increased H3K4
methylation, and increased gene expression of canonical epidermal differentiation
genes.
Future studies will be needed to test the ability of LSD1 inhibitors, and
particularly the potential of topically delivered LSD1 inhibitors, to treat cSCC in vivo.
Along these lines, recent evidence has also highlighted the ability of LSD1 inhibitors to
synergize with immunotherapies such as inhibitors of PD-1 [21], suggesting even further
potential when used in combination with other therapies that have demonstrated efficacy
[40]. More broadly, this study also suggests that a deeper mechanistic understanding of
chromatin regulators in epithelial tissues may lead to novel therapeutic opportunities for
a range of cutaneous diseases. For instance, psoriasis and acne, two diseases that
affect broad segments of the population [188], have also been shown to benefit from
therapies thought to work through pro-differentiation mechanisms [189].
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(M) BPs associated with genes upregulated in siLSD1 and by 2d or 6d GSK-LSD1 (29 genes).
(N) Heatmap of DEGs (log2 fold changes) for the set of genes commonly upregulated by siLSD1
and by 2d or 6d GSK-LSD1 (29 genes). All BPs determined by GO PANTHER analysis.
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and SNAI2 knockdown (I) or downregulated by 2d GSK-LSD1 and SNAI2 knock-down (H) and by
6d GSK-LSD1 and SNAI2 knock-down (J). (K) BPs associated with genes found commonly
upregulated by 2 days of GSK-LSD1-treatment or SNAI2 knockdown. (L) Representative result of
Co-IP experiments from human EPs using anti-LSD1 or anti-SNAI2 antibodies. (M-N) UCSC
tracks illustrating the common binding of LSD1 and SNAI2 at two keratinocyte differentiation
genes, CLDN7 (M) and PPL (N), and how GSK-LSD1 treatment affects both LSD1 binding and
transcription of LSD1 bound genes (top tracks) and ChIP-seq (bottom tracks)
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Figure S4. H3K4 methylation marks are enriched at gene promoters and show increased deposition near sites where LSD1
binding is lost while inhibition of LSD1 activates epidermal differentiation genes and inhibits squamous cell carcinoma

Fig. S7.
(A) Genomic distribution of H3K4me1/me2 marks in DMSO- or GSK-LSD1-treated EPs,
invasion in a 3D organotypic model of epidermal neoplasia. LSD1 expression also inversely correlates with the expression
of epithelial differentiation genes in head and neck squamous cell carcinoma (HNSCC). Related to Figures 3 and 4. A.
Genomic distribution of H3K4me1/me2 marks in DMSO- or GSK-LSD1-treated epidermal progenitors, numbers at the top of
numbers
at the top of each bar represent the log2 enrichment for a particular class of genomic
each bar represent the log2 enrichment for a particular class of genomic annotation as determined by HOMER. B. Heatmaps
representing LSD1, H3K4me1 and H3K4me2 binding enrichment +/- 2kb apart center of GSK-LSD1 differential LSD1 peaks (eg,
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keratinocytes transfected with constitutively activated mutant CDK4 (R24C) and tamoxifen-inducible mutant H-RAS (G12V) with
either inactivated (tamoxifen - ) or activated H-RAS (tamoxifen +) as compared to corresponding DMSO controls determined by
immunoblotting. F. Immunofluorescence staining of oncogenic keratinocytes transfected with constitutively activated mutant
CDK4 (R24C) and activated H-RAS mutation treated with GSK-LSD1 (20µM) or vehicle (DMSO) for the epidermal
differentiation markers Involucrin (red) and Filaggrin (green) or DAPI nuclear stain (blue). Magnification: 20X, scale bar =50µM
G. Transcriptional correlation plots for human HNSCC data from TCGA show that LSD1 expression negatively correlates with
expression of canonical epidermal differentiation transcription factors while being positively correlated with SNAI2 expression. Pvalues retrieved from TCGA.
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(eg,

GSK-LSD1-lost LSD1 sites, DMSO/GSK-LSD1-shared LSD1 sites and GSK-LSD1-gained LSD1
sites). (C) UCSC browser track example of a locus with increased H3K4me1 and a GSK-LSD1lost LSD1 site, but no increase in H3K4me2 (TCF7). (D) UCSC browser track example of a locus
with GSK-LSD1-lost LSD1 site without any concomitant GSK-LSD1-gained H3K4me1 or
H3K4me2 (VIM). (E) NOTCH3, GRHL3, and AP2-γ are upregulated in GSK-LSD1-treated (2 μM)
oncogenic keratinocytes transfected with constitutively activated mutant CDK4 (R24C) and
tamoxifen-inducible mutant H-RAS (G12V) with either inactivated (tamoxifen -) or activated HRAS (tamoxifen +) as compared to corresponding DMSO controls determined by immunoblotting.
(F) IF staining of oncogenic keratinocytes transfected with constitutively activated mutant CDK4
(R24C) and activated H-RAS mutation treated with GSK-LSD1 (20μM) or vehicle (DMSO) for the
epidermal differentiation markers Involucrin (red) and Filaggrin (green) or DAPI nuclear stain
(blue). Magnification: 20X, scale bar =50μM (G) Transcriptional correlation plots for human
HNSCC data from TCGA show that LSD1 expression negatively correlates with expression of
canonical epidermal differentiation transcription factors while being positively correlated with
SNAI2 expression. Pvalues retrieved from TCGA.

Additional supplementary data files (RNA- and ChIP-sequencing files) are
available at https://www.cell.com/action/showPdf?pii=S22111247%2819%2930962-3.
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3.5 Methods

Normal Human Epidermal Keratinocyte Isolation and Culture
Primary epidermal progenitors were isolated from de-identified discarded
neonatal human foreskin obtained by Core B of the Penn Skin Biology and Diseases and
Resource-based Center. Foreskin was incubated for 12 h at 4°C in 2.4 U/mL Dispase II.
Sterile forceps were used to separate the underlying dermis. The epidermal sheet was
transferred to a 60-mm tissue culture plate, incubated in 0.25% trypsin for 10 min at
37°C, and then neutralized with 1 mL of fetal bovine serum (FBS). Sterile forceps were
used to scrape the epidermal sheet against the dish to dissociate cells. The suspension
was passed through a 40-mm strainer and then centrifuged at 200 g for 5 min. The cell
pellet was resuspended in 5 mL keratinocyte medium (described next). Epidermal
progenitors were cultured in a 50:50 mix of 1 × keratinocyte–SFM supplemented with
human recombinant epidermal growth factor and bovine pituitary extract combined with
medium 154 supplemented with human keratinocyte growth supplement and 1% 10,000
U/mL penicillin–streptomycin at 37°C.
Human Skin Organoids
Collagen Rafts: The 3D organotypic human skin cultures were performed as
described previously [144]. Briefly, J2 3T3 fibroblasts were grown in DMEM + 10% FBS.
Cells were released from culture plates using 0.25% trypsin for 5 min at 37°C,
resuspended in DMEM + 10% FBS, and counted using a hemacytometer to determine
the volume needed to obtain 0.75 million to 1 million fibro-blasts per organotypic culture.
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The required volume was centrifuged in a 50-mL sterile conical tube at 200 g for 5 min,
and the supernatant was removed. The fibroblast cell pellet was resuspended in 1/10 the
final required volume (2 mL per culture) of 10 × collagen resuspension buffer (1.1 g of
NaHCO3 plus 2.39 g of HEPES in 50 mL of 0.05 N NaOH) and held on ice. One-tenth
the final volume of 10 × DMEM (Sigma) was then added, and the cells were mixed by
vigorous pipetting. Purified high-concentration rat tail collagen I (Corning) was added
and diluted with sterile dH2O to a final concentration of 4 mg per milliliter of the final
volume. NaOH (0.05 N) was added to a pH of ~7. The collagen–fibroblast slurry was
mixed by inverting, and then 2 mL was pipetted into the upper chamber of a sixwell
transwell insert (Corning) placed within a deep-well six-well tissue culture plate
(Corning). The fibroblast– collagen matrices were allowed to polymerize for 60 min at
37°C. Next, the matrices were submerged in DMEM + 10% FBS and placed overnight at
37°C. The next day, NHEKs were trypsinized, resuspended in 38 DMEM + 10% FBS,
counted to collect 1 million cells per culture, and centrifuged at 200 g for 5 min, and the
supernatant was discarded. The NHEK pellet was resuspended in E-medium
supplemented with 5 ng/mL EGF (Sigma) to a volume of 2 mL per culture. The DMEM
was removed from both the upper and lower chambers of the transwell plates containing
the collagen–fibroblast matrices. Two milliliters of NHEKs (1 million cells) was seeded
atop each matrix in the upper transwell chamber, and 14 mL of E-medium with 5 ng/mL
EGF was added to the bottom chamber. The cultures were placed overnight at 37°C.
The next day, the medium was aspirated from both the top and bottom chambers of the
transwell. To place the NHEK monolayers at an air–liquid interface and induce
stratification, 10 mL of E-medium (without EGF supplementation) was added only to the
bottom chamber of the transwell, and the cultures were grown for up to 12 d at 37°C and
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fed 10 mL of Emedium every other day. To generate protein lysates, the transwell
apparatus was removed from the plate, and the organotypic culture was separated from
the underlying matrix using sterile forceps. The culture was transferred into urea sample
buffer (8 M urea, 1% SDS, 10% glycerol, 60 mM Tris, 5% β-mercaptoethanol at pH 6.8)
and dissolved by vigorous pipetting using a 25-gauge needle and a 1-mL syringe.
Organotypic cultures were prepared for routine histology by submerging the culture in
10% neutral-buffered formalin for 24–48 h
Organotypic Culture: Split-thickness human skin was obtained from SBDRC.
Skin was washed in PBS containing 5% penicillin-streptomycin and incubated at 37°C
for 10 days in PBS with penicillin-steptomycin, where PBS was changed every 2 days.
The epidermis was separated from the dermis and discarded. The dermis was washed
with PBS and incubated at 4°C for 6 to 12 weeks, with PBS changed every 2 days. For
assembly of organotypic tissue, the dermis was cut into 1 cm2 square pieces. The cut
dermis was elevated onto a sterilized annular dermal support tissue culture device in a
manner that the basement membrane was oriented upward. 50 uL Matrigel was added
to the bottom (non-basement membrane) side of the dermis to block any openings in the
dermis due to hair follicles and incubated at 37°C for 30 minutes until solidified. Primary
human keratinocytes with CDK4 R24C and ER-H-RAS G12V overexpression were
seeded onto the basement membrane side at a density of 8×105 cells in a total volume
of 80 µL. Keratinocyte growth medium (KGM) was added below the dermal support
device allowing the basement membrane side to be exposed to air. KGM consists of 3:1
mixture of DMEM:Ham’s F12, supplemented with 10% FBS, adenine (1.8 × 10–4 M),
hydrocortisone (0.4 µg/ml), insulin (5 µg/ml), cholera toxin (1 × 10–10 M), EGF (10
ng/ml), transferrin (5 µg/ml), and triido-lthyronine (1.36 ng/ml). KGM medium was
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changed every other day, along with any 4- hydroxytamoxifen (100 nM in 100% EtOH) to
activate H-RAS. Organotypic tissue was harvested after 14 days, fixed in 10% formalin
overnight, and placed in 70% EtOH for paraffin embedding.
Retroviral Transduction: Phoenix cells were used for retrovirus production
containing ERH-RAS G12V and CDK4 R24C constructs [190]. Phoenix cells containing
either construct were plated in a 6-well plate at approximately 40% confluency. 24 hours
after plating, cell culture medium was replaced, and cells were moved to 32°C for
optimal virus production. Primary human keratinocytes were transduced at 30%
confluence. Cells were spun at 1000 rpm for 1 hour at room temperature and
keratinocyte growth medium was replaced after 1 hour of incubation at 37°C. Primary
human keratinocytes were first transduced with CDK4 R24C and then two days later
were transduced with ER-H-RAS G12V. Overexpression of both vectors was confirmed
with western blot; for ER-H-RAS, 100 nM 4-hydroxytamoxifen was added for 72 hours
before collecting cells for western blot and was confirmed via downstream activation of
p-ERK. Keratinocytes containing both CDK4 and ER-H-RAS were frozen and thawed for
each experiment
LSD1 Inhibitor
For LSD1 inhibitor experiments, epidermal progenitors were treated with LSD1 inhibitors
GSK-LSD1 or 2-PCPA. For 48 hour experiments, cells were treated twice with inhibitor
at 0 and 24 hours before harvesting. For 6d experiments, cells were treated once daily
with inhibitor at 0, 24, 48, 72, 96, and 120 hours before harvesting at 144 hours.
Differentiation Media
For differentiation experiments, NHEKs were cultured in medium containing 1.22
mM calcium chloride for 48 h and then harvested.
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siRNAs
For siRNA experiments, primary human epidermal progenitors were treated with
either siRNAs against LSD1 or a control siRNA at a dose of 500 nM. Cells were
harvested 72 hours after transfection.
RNA-sequencing
Total RNA was extracted using RNeasy kit following the manufacturer’s
instructions. All RNA-seq libraries were prepared using the NEBNext poly(A) mRNA
magnetic isolation module followed by NEBNext Ultra Directional RNA library
preparation kit for Illumina. Library quality was checked by Agilent BioAnalyzer 2100 and
libraries were quantified using the Library Quant Kit for Illumina. Libraries were then
sequenced using a NextSeq500 platform (75-base-pair (bp) single-end reads). All RNAseq was aligned using RNA STAR [150] under default settings to Homo
sapiens University of California at Santa Cruz (UCSC) hg19 (RefSeq and Gencode gene
annotations). FPKM (fragments per kilobase per million mapped fragments) generation
and differential expression analysis were performed using DESeq2 [151]. Statistical
significance was obtained using an adjusted p value (padj) generated by DESeq2 of less
than 0.05. All RNA-seq experiments were performed in triplicate. For Figure 5N, the list
of human genes that defines the gene ontology term ‘‘Keratinocyte differentiation’’
(GO:0030216) was filtered to retrieve genes that have a positive log2 fold change and
an adjusted p value ≤ 0.05 in the epidermal differentiation RNA-seq dataset, and then
further filtered to keep genes that have sufficient expression to assess differential gene
expression in both 2d and 6d GSK-LSD1 RNA-seq datasets (i.e., baseMean > = 10),
and then ordered by decreasing log2 fold change in the epidermal differentiation RNAseq dataset.
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ChIP-sequencing
ChIP-seq was performed as described previously [59, 191]. Briefly, keratinocytes
cultured in 10-cm2 dishes were fixed in 1% formaldehyde for 5 min, and fixation was
quenched with the addition of glycine to 125 mM for an additional 5 min. Cells were
harvested by scraping from plates and washed twice in 1 × PBS before storage at –
80°C. ChIP extracts were sonicated for 15 minutes in a Covaris sonicator. All ChIPs
were performed using 500 µg of extract and 2 µg of antibody per sample. Thirty
microliters of Protein G Dynabeads was used per ChIP. ChIP DNA was also used to
make sequencing libraries using NEBNext Ultra DNA library preparation kit for Illumina.
Library quality was checked by Agilent BioAnalyzer 2100 and libraries were quantified
using the Library Quant Kit for Illumina. Libraries were then sequenced using a
NextSeq500 33 platform (75-bp, single-end reads). After sequencing, all data were
demultiplexed from the raw reads using Illumina’s BCL2FASTQ from BaseSpace.
Further ChIP-seq analysis described below. Antibodies used for ChIP-seq include antiLSD1, anti-Histone 3 (monomethyl K4), and anti-Histone 3 (dimethyl K4) as described in
the KRT.
ChIP-sequencing Data Processing
ChIP-seq reads were aligned to human reference genome (hg19) using Bowtie2
V2–1.0 [153]. Only uniquely mapped reads were considered for further analysis. Aligned
reads form biological replicates were pooled together. For LSD1 ChIP-seq analysis, tag
directories were generated for pooled DMSO treated samples and for pooled GSKLSD1-treated samples using HOMER v4.10.1 [155], allowing a maximum of 1 tag per
base pair to remove PCR duplicates and using the given fragment length. Peaks were
called for pooled vehicle-treated samples and for pooled GSK-LSD1-treated samples
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using HOMER v4.10.1, using the corresponding inputs and default parameters.
Visualization tracks were generated using HOMER v4.10.1, allowing a maximum of 1 tag
per base pair to remove PCR duplicates, normalizing experiments to 10 millions total
tags and subtracting the corresponding input (-tbp 1, -i -subtract) and visualized using
UCSC Genome Browser [192]. For the differential analysis of LSD1 peaks, DMSOtreated and GSK-LSD1-treated peak sets were concatenated, then sorted and merged
using BEDtools v2.27.1 [193, 194], allowing a maximum distance of 100 base pairs (bp)
to merge peaks. The resulting peak file was gene annotated and reads were counted in
each tag directories and normalized to fragments per kilobase mapped (FPKM) using
HOMER v4.10.1. To retrieve high confidence peaks, the peak file was filtered to retrieve
peaks with a read count greater than 2.5 FPKM in both condition (e.g., DMSO-treated or
GSK-LSD1-treated). Differential peaks were defined as GSK-LSD1-lost if the read
counts in DMSO-treated samples were at least 2 times higher than in GSK-LSD1-treated
samples. Identically, peaks were defined as GSK-LSD1 gained if the read counts in
GSK-LSD1-treated samples were at least 2 times higher than in DMSO-treated samples.
Heatmaps and average profile plots were generated by annotating the corresponding
peaks sets using HOMER v4.10.1 and custom R 34 scripts. Analysis of transcription
factor motifs at each peak set was performed using HOMER v4.10.1 and a fragment size
of 200 bp, scaling sequence logos by information content. Gene ontology analyses of
DMSO / GSKLSD1-shared LSD1 sites, GSK-LSD1-lost LSD1 sites and GSK-LSD1gained LSD1 sites were performed using HOMER gene ontology annotation, using the
default genome size (2e9) and the default genome background. SNAI2 ChIPseq reads
were retrieve form GEO GSE55421 and processed as described above, filtering out
peaks with a FPKM lower than 2.5. Overlap between sets of LSD1 peaks and SNAI2
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peaks was assessed by merging peak files, using HOMER v4.10.1, allowing a maximum
merging distance of 1000 base pairs. For H3K4me1 and H3K4me2 ChIP-seq analysis,
broad peaks were called in each condition on pooled biological replicates using macs2 v2.1.1.20160309 using a broad-cutoff of 0.05 and default parameters [195]. Differential
peaks were identified using macs2 bdgdiff default parameters. The resulting peak file
was merged using BEDtools v2.27.1, in order to stitch together differential peaks up to 5
kilobases (kb) apart. Genomic distribution, average profile plots, heatmaps and
visualization tracks of H3K4me1 and H3K4me2 in DMSO-treated samples and in GSKLSD1-treated samples as well as differential H3K4me1 and H3K4me2 regions were
retrieved by annotating the corresponding sets of peaks using HOMER v4.10.1, as
described above. Overlaps between GSK-LSD1-gained H3K4me1, GSK-LSD1 gained
H3K4me2 regions and GSKLSD1-lost LSD1 sites were assessed on peak-associated
genes by associating those peaks with the nearest gene’s transcriptional start site using
HOMER v4.10.1 and a custom R script.
Transcription Factor Analyses
The list of human transcription factors representing 2,765 transcription factorencoding genes was derived from [196].
Growth Curve Measurements
210,000 epidermal progenitors were seeded on a 10 cm surface area on day 0.
Cells were treated with DMSO or GSK-LSD1 (2 µM) the following day and retreated at
the same time a day later. On day 3, cell number was measured with a Countess
automated cell counter (Life Technologies) following standard procedures and default
parameter settings. 210,000 cells were plated back into non-drug media. The following
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day, the drug regiment proceeded as before with cell number being counted every 2
days for a total of 12 days.
Immunoblotting
Cell were washed twice with PBS and lysed with RIPA buffer (Sigma, Cat#
R0278) supplemented with Halt protease and phosphatase inhibitors (Thermo Fisher,
Cat# 78440). Lysates were incubated at 4°C for 15 min, sheared with a 25 g needle, and
then pelleted at 15 000 rpm for 10 min at 4°C. Supernatants were quantified using the
Bradford Assay (Quick Start Bradford 1X Dye Reagent from Bio-Rad, Cat# 500–0205).
Samples were separated by electrophoresis in 4%–20% SDS/PAGE gels with 20 µg per
lane, transferred to PVDF membrane, and blotted with antibodies. Secondary
horseradish peroxidase-conjugated secondary antibodies (Santa Cruz) and Amersham
ECL Prime Western Blotting Detection Reagents (GE Healthcare, Cat# RPN2232) were
used for detection. Antibodies used for immunoblotting include anti-GRHL3-C12, antiNOTCH3-D11B8, anti-KLF4, anti-AP-2γ, anti-LSD1, and anti-Slug.
Co-immunoprecipitation Experiments
Co-immunoprecipitations experiments were performed as previously described
[156]. Briefly, 30 µL of magnetic Protein G Dynabeads were washed twice in 1 mL BSA
0.5%, resuspended in 250 µL BSA 0.5% and conjugated for 1h to 2h at 4°C under
rotation with 1 µg of antibodies against either LSD1, SNAI2, or IgG as a negative control.
About 500,000 proliferating epidermal progenitors cells were harvested from a 10 cm
culture plate at 50% confluence and lysed for 1h at 4°C under rotation in 250 µL of
immunoprecipitation buffer (IP buffer: 20 mM Tris pH 7.5, 134 mM NaCl, 1 mM CaCl2,
1% NP-40, 10% 36 glycerol, supplemented with freshly made 1 mM MgCl2, 1:100 Halt
protease and phosphatase inhibitor cocktail (Thermo Fisher, Cat# 78440) and
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benzonase at 12.5 U ml-1. Benzonase is critical for the efficient release of chromatinbound proteins to the supernatant and MgCl2 is critical for its activity. Cell lysates were
centrifuged at top speed for 10 minutes. 500 µg cell lysate were incubated overnight at
4°C with antibody conjugated magnetic beads previously washed 3 times with 1 mL BSA
0.5%. Immunoprecipitates were collected using a magnet, washed four to five times with
IP buffer devoid of MgCl2, protease/phosphatase inhibitors and benzonase, then boiled
with NuPage loading dye and analyzed by western blotting. Antibodies used for Co-IP
include anti-LSD1, anti-Slug, and anti-IgG as described in the KRT.
Immunofluorescence
3D organotypic skin cultures were processed for histological examination by
Core A of the Penn Skin Biology and Disease Resource-based Center. Tissue slides
were exposed to xylene and ethanol and then treated with Targeting Unmasking Fluid
(Pan Path, Cat# Z000R.0000) to deparaffinize the tissues. Sections were incubated in
BlockAid Blocking Solution (Thermo Fisher, Cat# B10710) for 2 h at 37°C and then
incubated O/N in primary antibody. Following secondary antibody incubation and
washes, the sections were mounted with ProLong Gold with DAPI (Thermo Fisher,
Cat# P36935). The slides were observed and representative images captured using a
Keyence BZ-X700 Series All in One Fluorescent Microscope and a Nikon Eclipse
microscope. Antibodies used for IF include anti-KRT14, anti-Collagen VII, anti-IVL, and
anti-Filaggrin as described in the KRT. All IF figures appear at 20x magnification and are
marked by scale bars equal to 50 µm.
Human Skin Organoid LSD1 Inhibitor Assays
Collagen Rafts: Skin organotypics established on a collagen raft were treated
with DMSO or GSK-LSD1 every 48 hours starting on day 0 and harvested after 7 days.
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Devitalized Human Dermis: KGM media containing 4-hydroxytamoxifen (100 nM
in 100% EtOH) and DMSO or GSK-LSD1 was replaced daily and organotypic tissue was
harvested after 12 days.
Experimental Design
The number of experimental replicates are detailed in the figure legends and
represent independent biological experiments. Experiments were not randomized and
investigators were not blinded to allocation during experiments and outcome
assessment.
Statistical Analysis
All statistical tests for experiments and the corresponding P values are detailed in
the figure legends. P values less than 0.05 are considered statistically significant and
higher levels of significance are noted in the figures and figure legends. Statistical details
for specific experiments are described in further detail below. For gene overlaps,
statistical significance of overlaps between lists of genes or list of unique genes
associated with ChIP-seq peaks were assessed using the R package GeneOverlap
which relies on a Fisher’s exact test to calculate the statistical significance of the
overlap. The union of genes or transcription factors expressed in proliferating epidermal
progenitors upon GSK-LSD1 treatment or 2-PCPA-treatment was used as a background
(14,104 genes and 2,134 transcription factors, respectively). Statistical analyses
performed for all RNA-seq and ChIP-seq data are detailed in the method details. For
RNA-seq data, genes were considered significantly up- or downregulated if the adjusted
p value generated by DESeq2 for that gene was less than 0.05. Gene ontology analyses
were either performed using PANTHER [197] or HOMER as stated in figure legends
using the indicated background genes as a reference list. PANTHER gene ontology

84

overrepresentation tests rely on the use of a Fisher’s exact test together with a
Benjamini-Hochberg False Discovery Rate (FDR) correction. HOMER gene ontology
analyses were performed using HOMER’s annotatePeaks.pl script. Enrichment of gene
ontology terms is calculated assuming a cumulative hypergeometric distribution.
Genomic annotation of LSD1 and H3K4me1/me2 binding sites and their corresponding
enrichment (log2) were calculated using HOMER annotatePeaks.pl scripts. Transcription
factor binding motifs at LSD1 binding sites and their respective statistical significance
were computed using HOMER findMotifsGenome.pl script which uses ZOOPS scoring
(zero or one occurrence per sequence) coupled with the hypergeometric enrichment
calculations (or binomial) to determine motif enrichment. For transcriptional correlation
plots, P values were retrieved from TCGA. For epidermal area and protrusion
quantification, four representative images of each biological replicate for each condition
(DMSO versus LSD1 inhibitor treatments) were used to determine the average
epidermal area or number of protrusions of an individual sample. These values were
utilized in a one-way ANOVA and a post hoc Tukey’s multiple comparisons test to
determine significance between groups using GraphPad Prism 7.04. Epidermal area
was determined using ImageJ [198]. For the growth curve measurement assay, a 2tailed Student’s t test was used to determine significance using GraphPad Prism 7.04.
Data and Code Accessibility
The accession number for all data is GEO: GSE133766. The accession number
for the ChIP-seq data reported in this paper is GEO: GSE133560. The accession
number for the two RNA-seq datasets are GEO: GSE133737 and GSE133738. Cutsom
R scripts used in this study are available upon request.
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Chapter 4: Conclusions and future directions

4.1 Conclusions and future directions, chapter 2
In chapter 2, we determined the effects of Mll4 and Mll3 deletion alone and in
combination in the epidermis if mice. Here, we discuss the four major conclusions from
this work, summarize their impact, as well as discuss future directions. First, we found
that Mll4 deficiency in the epidermis of mice altered differentiation and promoted
neoplastic proliferation. This suggests that in the epidermis, MLL4 most likely acts as a
tumor suppressor and that its loss of function in human skin contributes to the initiation
of cSCC. This is in line with observations that MLL4 mutations are associated with early
clone formation in normal epithelial tissues [66] and reports showing pervasive MLL4
mutations in cSCC (>50%). Testing the impact of Mll4 loss during carcinogenesis by
employing in vivo cSCC models is one exciting future direction for this work. Additionally,
this data provides impetus to determine if Mll4 loss in other epithelial tissues causes
similar premalignant changes.
Second, we found that a loss of Mll4 leads to profound transcriptional alterations,
likely due to both direct regulation of gene expression via enhancer regulation, as well as
secondary, indirect effects. Among the most significantly downregulated genes were key
factors involved in differentiation, barrier function, as well as the lipoxygenase pathway,
while upregulated genes were involved in fatty acid metabolism. These transcriptional
insights are key to explaining how MLL4 loss may drive cSCC and also highlight the
importance of MLL4 during normal epidermal homeostasis. Indeed, underscoring the
critical nature of many of the Mll4-down regulated genes, mutations in a number of them
are causative in a variety of human genetic skin disorders such as Col7a1, Fermt1,
Slurp1, Alox12b, and Aloxe3 [199-201] . Further, integration of these data with our ChIP-
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seq findings revealed that MLL4 likely mediates these effects through recruitment by p63
(in line with our previous findings [59]) and/or p53, our top two most enriched motifs.
Further supporting this data, here we provide the first evidence that MLL4 directly binds
wild type p53 shown by Co-IP (Figure 4) as well as through unbiased coimmunoprecipitation mass spectrometry approaches (data not shown). This suggests a
potential, functional connection between these two factors likely critical during
tumorigenesis, given that together MLL4 and p53 are among the topmost commonly
mutated genes in all of cancer. Further, this supports the idea that while MLL4 may be a
general factor required for enhancer priming and activation, it may also regulate
transcription in more specific ways by integrating developmental cues mediated by p63,
or tumor suppression pathways via p53. Future studies should better characterize the
relationship between MLL4 and p53, how this impacts transcription of their respective
gene targets, how their mutation in tumors impacts these functions, and if this plays a
functional role in cancer.
Our third major conclusion from chapter 2 is that Mll4 is the major H3K4me1
histone methyltransferase in the skin, but Mll3 is not wholly dispensable, and indeed
partially compensates for Mll4 loss. Given the similarity of MLL4 and MLL3, this finding is
intriguing from a fundamental epigenetic standpoint and likely tied to unique, noncatalytic
functions. However, the different functions and binding partners between MLL4 and
MLL3 remain poorly understood. Future experiments to dissect these differences are
warranted and could explain the observed discrepant importance of these enzymes in
the skin and identify potential unique functions in cancer. Finally, why complete loss of
both Mll4 and Mll3 is not compatible with life remains an open question. Future
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directions studying the embryonic development of mice lacking all the ability to catalyze
any H3K4me1 in the developing epithelium would fill this gap in knowledge.
Finally, our last major conclusion from chapter 2 is that Mll4 regulates ferroptosis,
a recently described form of programmed cell death. Mll4 loss uniquely rewired the
expression of key genes and markers of ferroptosis (Alox12, Gpx4, Slc7a11). These
data, combined with staining for ferroptotic markers, suggested that mice lacking Mll4
had an impaired ability to undergo ferroptosis which may have driven the disrupted
differentiation and neoplastic proliferation we observed (Figure 9). This is consistent with
recent evidence that p53 can mediate tumor suppression through Alox12-mediated
ferroptosis [134]. Significantly, this reveals a new mechanistic basis for MLL4-mediated
tumor suppression. If this is a more universal mechanism in other tissue types is of
significant interest given the pervasive nature of MLL4 mutations across human cancers.

Figure 9: Chapter 2 concluding model. Knockout of Mll4 leads to a reduced expression of proferroptotic Alox enzymes and increased expression of the antiferroptic factors Slc7a11 and Gpx4.
Collectively, these reduces the accumulation of lipid peroxides and ferroptosis.
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Importantly, these findings prompted us to wonder what basic physiological roles
ferroptosis may have in the epidermis. Staining for ferroptotic markers in human skin, as
well as iron chelation experiments in 3D organotypic skin models, suggested that
ferroptosis is essential in mediating normal epidermal differentiation. Indeed, although
cell death is a basic feature of terminal differentiation in the epidermis, the exact mode of
cell death utilized during this process is not known and generally referred to as
“cornification” [26]. Interestingly, cornification and ferroptotic cell death share key
features including an accumulation of lipid peroxides subsequently followed by a
sustained intracellular influx of calcium that promotes cell death [202-204]. Another key
feature of keratinocyte terminal differentiation is the disintegration of key cellular
membranous organelles, the most common site in which lipid peroxides accumulate [28,
140]. Although more speculative, we think it is possible that ferroptotic mediated-lipid
peroxide accumulation in membranous organelles in keratinocytes may compromise
organellar function, both triggering their disintegration as well as cell death signaling
pathways. For example, an attractive hypothesis is that an accumulation of lipid
peroxides in the endoplasmic reticulum (ER), the most critical site of intracellular calcium
storage, may compromise its integrity both promoting its disintegration as well as the
release of calcium to trigger terminal differentiation signaling cascades. Indeed, calcium
ions play one of the most essential roles in promoting keratinocyte differentiation, a
mechanism that interplays with ER stress [205, 206]. All together, these data and
conjectures put forth the provocative idea that keratinocyte cell death via cornification is
partially, if not wholly, driven by ferroptosis, failure of which may drive the initiation of
cSCC. Future experimentation will test this idea and reveal if ferroptosis is, in fact, an
essential mediator of differentiation and tumor suppression in the epidermis. Perhaps
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most importantly, given the ability to pharmacologically induce ferroptosis through
inhibitors of targets such as GPX4 and SLC7A11 [135, 136], these data suggest a
potentially new therapeutic strategy for treating cSCC, but also epithelial SCC cancers
as a whole. However, ferroptosis targeting compounds suffer from a lack of specificity as
well as toxicity and have yet to be tested in any clinical setting, currently limiting the
potential of this approach [136]. Nonetheless, our findings presented here vastly expand
our understanding of the fundamental, physiological roles of ferroptosis in organismal
homeostasis and how this may become dysregulated to drive disease. This provides
impetus for additional studies with the ultimate goal of bringing new therapeutic options
to patients suffering with disease, including cancer.

4.2 Conclusions and future directions, chapter 3
In chapter 3, we studied the effect of pharmacological inhibition of LSD1 in
epidermal cell in vitro. Here, we discuss three major conclusions from this work,
summarize their impact, as well as discuss future directions. First, using two different
LSD1 inhibitors in keratinocyte progenitors in vitro we found that LSD1 inhibition
unleashed the epidermal differentiation transcriptional program including activation of
key fate-determining transcription factors (e.g., NOTCH3, GRHL3, KLF4). Building on
this, second, we found that LSD1 inhibition prevented LSD1 binding at SNAI2-repressed
epidermal differentiation genes and was coupled with increases in H3K4 methylation at
gene regulatory regions of these genes. This is in line with previous reports identifying
that SNAI2, acting through its SNAG domain, can recruit LDS1 to target genes [96], but
is the first demonstration of this interaction in the epidermis. These data provide a
mechanistic explanation for the observed effects of SNAI2 in repressing differentiation in
keratinocytes [180]. However, given the key roles of the Snail family of transcription
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factors in mediating EMT in various systems, including cancer, these data point to a
mode of targeting potential SNAI2-LSD1 EMT mediated effects in the skin, particularly in
targeting invasiveness in cSCC tumors. Indeed, our third major conclusion from this
study was that LSD1 inhibition functionally resulted in reduced proliferation of
keratinocyte progenitors and reduced growth and invasion in a model of cSCC. Critically,
these data point to the idea that LSD1 may be viable therapeutic target in cSCC (Figure
10), an idea we explored in detail in the following review [2].

Figure 10: Chapter 3 concluding model. LSD1 is recruited to gene regulatory regions for
epidermal differentiation genes via SNAI2 and removes the activating chromatin marks
H3K4me1/2 to repress gene expression. These functions are lost through the use of LSD1
inhibitors and repress features of cSCC in a 3D organotypic model.

We anticipate that these effects would be particularly pronounced in the context
of MLL4 mutation and dysfunction. Future studies will be needed to directly test the
ability of LSD1 inhibitors to treat cSCC in vivo. Indeed, the work started here has
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prompted us to formulate a topical LSD1 inhibitor to be tested for this purpose and is
presently ongoing work. Along these lines, recent evidence has pointed to the ability of
LSD1 inhibitors to synergize with immunotherapies such as blockers of PD-1 [21]. Given
the recent approval of PD-1 blockade therapy for use in cSCC [40], there is an even
greater motivation to determine if LSD1 inhibitors may be a viable therapeutic target in
this cancer. LSD1 inhibitors may also prove efficacious in treating skin diseases beyond
cancer, given their ability to promote epidermal differentiation. Future directions
investigating the ability of LSD1 inhibitors to treat these skin diseases, among others,
holds great therapeutic promise. Together, these observations and proposed in vivo
pharmacological experiments call for a more comprehensive understanding of the role of
LSD1 during epidermal development and homeostasis in vivo.

4.3 Concluding remarks
The collective integration of these data from transgenic mice, next-generation
sequencing, and human skin models has filled major gaps in knowledge regarding the
roles of the MLL4-LSD1 epigenetic axis during epidermal homeostasis, differentiation,
and tumorigenesis. Beyond revealing fundamental insights into the critical functions of
this epigenetic axis in the epidermis, these findings also lay the foundation for novel
clinical approaches in skin disease with the ultimate goal of delivering therapeutic
benefits to patients.
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